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ABSTRACT 
 
DEVELOPMENT OF A SYSTEMIC LUPUS ERYTHEMATOSUS KNOWLEDGE 
QUESTIONNAIRE: THE RELATIONSHIP AMONG DISEASE PROXIMITY, 
EDUCATIONAL EXPOSURE, AND KNOWLEDGE 
 
by 
Shelbie L. Sullivan 
The University of Wisconsin-Milwaukee, 2016 
Under the Supervision of Professor Katie E. Mosack 
 
 
There are an estimated 1.5 million people living with systemic lupus erythematosus (SLE), a 
multisystem autoimmune disorder with a high risk of co-morbid health concerns. The 
psychological consequences of an SLE diagnosis result in increased daily stress, anticipated 
stigma, fears of rejection, and increased self-consciousness, all of which can decrease a patient’s 
quality of life. In order to combat these negative experiences, attempts to increase accurate 
knowledge of SLE and extinguish SLE misconceptions must be made. The current study aimed 
to 1) create a medically informed SLE knowledge questionnaire; 2) determine the rate of 
community members’ SLE knowledge; and 3) determine the relation that disease proximity and 
educational exposure have on community members’ knowledge of SLE. This novel study is the 
first to create an SLE knowledge questionnaire and provide evidence that having a closer 
personal relation to SLE increases SLE knowledge, as does having learned about SLE in an 
educational setting. 
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Development of a Systemic Lupus Erythematosus Knowledge Questionnaire: The 
Relationship Among Disease Proximity, Educational Exposure, and Knowledge 
 
Chronic disease affects nearly 50% of Americans, which means approximately 117 
million people are living with at least one chronic condition (Ward, Schiller, & Goodman, 2014). 
Systemic lupus erythematosus (SLE) is one example of a chronic disease that has physical, 
psychological, financial and social implications for individuals who are diagnosed. According to 
the American Autoimmune Related Diseases Association (AARDA), in 2011 SLE cost around 
$20,000 a year per patient in direct and indirect healthcare costs. Nationally speaking, SLE costs 
somewhere between $2.2 billion and $9.6 billion dollars a year.  
Systemic lupus erythematosus is a rare and complex multisystem autoimmune disorder 
where one’s immune system is overactive and the body attacks its own organ systems (Mak, Ho 
& Lau, 2009; NIAMS, 2006). There are four specific variations of the illness cutaneous/discoid 
lupus, drug-induced lupus, neonatal lupus, and SLE. However, SLE is the most common 
diagnosis and makes up 90% of all broad lupus diseases. SLE is also most commonly referred to 
as “lupus,” while the other variations are referred to by their specific name. Due to the 
complexity of SLE and the diagnostic process, prevalence rates are quite difficult to calculate. 
The Lupus Foundation of America (n.d) reports that there are approximately 1.5 million cases of 
lupus and 70% of these cases are SLE-specific. However, newer studies have attempted to gather 
statewide prevalence rates rather than national rates (Pons-Estel et al., 2010; Somers et al., 2014; 
Feldman, et al., 2013; Helmick et al., 2008). More recent researchers’ findings estimate that there 
are 161,000 definite cases and another 322,000 probable cases of SLE to date (Helmick et al., 
2008) and approximately 6 newly diagnosed cases per 100,000 people each year (Pons-Estel et 
al., 2010; Somers et al., 2014). This uncertainty about the true number of SLE cases makes 
getting appropriate treatments difficult because so many patients are not aware of their diagnosis.  
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The specific cause of this abnormal immune functioning is not fully understood; 
however, both genetics and environmental factors play a role in disease onset (Bensler & 
Silverman, 2007). The disease is considered an invisible chronic illness due to the manifestations 
being largely internal in nature (NIAMS, 2006; Parrondo, 2011). This label is given because 
patients experience unique challenges in their life when diagnosed with an invisible illness that 
threaten their quality of life (QoL; Brennan & Creaven, 2015; Sutanto et al., 2013). Patients 
diagnosed with SLE report excessive uncertainty, hopelessness, and helplessness related to the 
experience of their invisible symptoms (Beckerman, Auerbach, & Blanco, 2011). Patients are 
also at an increased risk for psychiatric conditions, which further decrease their QoL.  
Patients often find that they must learn to identify and care for their physical symptoms 
quickly in order to manage their disease more effectively. This ability to monitor one’s disease is 
often times difficult as symptom expression and severity is extremely unpredictable (NIAMS, 
2006; Lau & Mak, 2009). Patients experience symptoms in flares, which is when symptoms 
occur in a variation of severity levels with a varying array of symptoms. The range of SLE 
symptom expression varies between mild disease activity and severe disease activity throughout 
patients’ lives (NIAMS, 2006). It is estimated that 50% of SLE patients will also manifest severe 
complications of the disease: nephritis (kidney inflammation), vasculitis in the central nervous 
system (inflammation of brain and spine blood vessels), pulmonary hypertension (deterioration 
of lung capillaries), interstitial lung disease (lung tissue scarring causing breathing difficulties), 
and stroke (Parrondo, 2011; Lam & Petri, 2005). 
A patient’s feelings of distress, guilt, and anxiety are due in large part to the negative 
social experiences they have with individuals who do not understand them and their illness 
(Brennan & Creaven, 2015; Earnshaw et al., 2012; Sutanto et al., 2013; Hale et al., 2006; Moses, 
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Wiggers, Nicholas, & Cockburn, 2005; Kozora, Ellison, & West, 2006). Attempts to understand 
how to improve the lives of patients have begun to move towards assessing the awareness that 
others, such as medical providers, family and friends and community members have of SLE 
(Brennan & Creaven, 2015; Hagger & Orbell, 2003; Karlson et al., 2004; Waldron et al., 2011; 
Young et al., 2002). In order to attempt to improve patients’ emotional and physical health new 
advocacy efforts need to extend to other groups’ awareness and knowledge of SLE.  
Epidemiology and SLE Disparities 
The cause of SLE is attributed to a combination of hormones, genetics, and 
environmental factors (e.g. ultraviolet rays or various chemical pollutants; Sestak, Nath, 
Sawalha, & Harley, 2007; Pons-Estel et a., 2010). Twin studies and familial studies have found 
that SLE is genetic in nature and as many as 100 currently identified genetic risk factors exist 
that remain latent until an environmental factor triggers onset (Sestak et al., 2007). SLE is 
disproportionately found in ethnic minority women and individuals of lower socioeconomic 
statuses (SES; Feldman et al., 2013). Genetic linkages, which are the specific order that genes 
are expressed on the chromosome, have also been identified within different ethnic groups 
(Harley, Kelly, & Kaufman, 2006). These linkages have been examined and many are unique to 
African American patients while other linkages have been identified for European-Americans or 
Hispanic-Americans (Sestak et al., 2007; Harley, Kelly, & Kaufman, 2006).   
It is not clearly understood to what extent environmental factors play a role in the onset 
of each case of SLE; however, two factors that have been identified as onset triggers are 
exclusively seen in women: estrogen and the XX chromosome (Crampton, Morawski, & 
Bolland, 2014). The overall diagnosis rate of SLE in women is 90%, where women are 
diagnosed nine times more often than men (Bensler & Silverman, 2007). Poverty and 
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disadvantages in one’s environment also plays a direct role in the survival rate of people with 
SLE (Durán, Apte, & Alarcón, 2007). A vast amount of scientific evidence has identified that the 
dominant group most commonly diagnosed with SLE are women of minority status in low SES 
environments (Marengo et al., 2012).   
Another disparity that exists for women is being of child-bearing age, which is 
considered to be between 15 and 45 years-old (Pons-Estel et al., 2010). Women with SLE who 
are pregnant or attempting to get pregnant are considered high risk due to the heightened risk of 
first and second-trimester premature births, low birth weights, and fetal deaths (NIAMS, 2006; 
Clowse, Magder, Witter, & Petri, 2005). Provided that women of childbearing age are at 
heightened risk of SLE onset, attempts to decrease the adverse effects for the baby and the 
mother’s health during pregnancy have been made. Medications are monitored more closely 
because some are not safe during pregnancy, which means women are taken off medications that 
manage their SLE (Clowse et al., 2005). Without these critical medications, disease activity 
increases. Increased disease activity during a pregnancy is one of the highest risk factors for 
infant mortality (Clowse et al., 2005). A delicate balance must be kept between medication 
management, disease activity, and monitoring a fetus’ and a mother’s health during pregnancy.  
Over the last 50 years, improvements in medical care have led to increased availability of 
medications, the creation of new medications, and new research. All of these advancements have 
helped to improve the life expectancy of SLE patients. In the 1950’s, approximately 50% of SLE 
patients died within 4 years of symptom expression and today survival rates are higher than 90% 
after 5 years (Pons-Estel et al., 2010; Harley, Kelly, & Kaufman, 2006). However, patients still 
suffer long-term decreases in QoL and increased medical costs (Pons-Estel et al., 2010). Even 
though medical advances have improved survival rates the disproportion of SLE diagnoses in 
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low SES and ethnic minority patients are still astronomical compared to non-white patients 
(Williams, Kamen, Penfield, & Oates, 2014). Therefore, increasing the awareness that patients 
and providers have for higher risk groups could improve the rates of accurate SLE diagnosis.  
SLE Education and Interventions 
As researchers learn more about SLE and the way that it impacts patients’ lives they have 
created various patient education programs (Cunningham & Kashikar-Zuck, 2013; Brown et al., 
2012; Ramos-Remus, Salcedo-Rocha, Prieto-Parra, & Galvan-Villegas, 2000). There have been 
two attempts at educating patients about SLE disease knowledge (Konttinen et al., 1991; Young 
et al., 2002). The researchers of these studies implemented and assessed the success rate of 
patient-specific education programs by providing patients with an educational resource (e.g. 
internet education website or patient education pamphlets). However, only two specific 
assessments have examined knowledge education with patients and there have been no attempts 
to examine the level of knowledge that medical providers, social supports or the general public 
have of SLE. The lack of attention given to knowledge levels for these other groups leaves a gap 
regarding ways to improve the lives of patients by increasing awareness of SLE.  
The first attempt to assess patient knowledge of SLE was in 1991 when Konttinen and 
colleagues provided SLE patients with a patient education guide and assessed pre- and post-test 
knowledge. Researchers created a patient guidebook that incorporated SLE disease information 
and positive coping mechanisms for patients. The researcher’s primary aim was to assess 
whether having access to a medically accurate SLE source would produce significant 
improvements in patient knowledge of their disease. The second aim was to examine whether 
being informed about positive coping behaviors would improve psychological well-being. 
Researchers concluded that psychological functioning did not change, but patients’ knowledge of 
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SLE did significantly increase over the course of the 8 to 10 weeks that knowledge was assessed. 
Konttinen and colleagues (1991) concluded that the improvement that their participants indicated 
that patients were interested in learning more about their disease and that learning more about 
their disease was beneficial for patients. 
Another attempt to test patients’ knowledge utilized an internet based information center 
for patients called LupusHelp (Young et al., 2002). The goal was to increase patient knowledge 
and researchers wanted to determine if having free online access to pamphlets, videos, and 
support groups related to SLE could further increase patients’ knowledge. Patients who 
completed the pre- and post-test knowledge test showed significantly improved knowledge. 
Indicating that for those who visited this LupusHelp web page and completed both the pre-and 
post- tests gained valuable knowledge of SLE. Although patients’ knowledge and well-being 
improved the researchers did not extend the benefits of this remote resource to other groups like 
the general public, medical providers, and social supporters.  
Psychological treatments and therapy options have developed and utilized a more 
collaborative technique for including disease education into treatments. Psychoeducation is the 
educational component in therapy that involves explaining to the client how treatment will 
specifically help their mental health concerns; however, when a patient has a comorbid physical 
condition the psychoeducation also includes specific disease information (Keefe, 1996). One 
way that psychoeducation is implemented is within the goals of Cognitive-Behavioral Therapy 
(CBT) methods (Keefe, 1996; Keefe, Somers, & Martire, 2008; Evers, Karrimaat, Van Riel, & 
De Jong, 2002). CBT treatment modules have been created to target the experience of pain 
associated rheumatologic conditions (Sharpe, 2003; Haupt et al., 2005). Clinicians use treatment 
goals to educate patients on how their disease can be managed and to teach skills specific to the 
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symptoms related to SLE (Rinaldi et al., 2006; Haupt et al., 2005). Evidence suggests that 
educating patients about their disease in therapy is related to improved health outcomes (Rinaldi 
et al., 2006; Thumboo & Strand, 2007).  
For SLE patients, interventions that incorporate these CBT therapeutic tools and illness-
specific information are associated with significant reductions in anxiety, depression, stress and 
disease activity (Karlson et al., 2004; Zhang, Wei, & Wang, 2012). However, disease education 
alone is not indicative of significant psychological improvements (Parker et al., 1988; Ottonello, 
2007). Ultimately, improvements in QoL occurs when disease knowledge is incorporated into 
psychological treatments. Although encouraging, this results in a disparity because it implies that 
only patients receiving psychological treatments are gaining the benefits of these successful 
results.  
The one research design that involved a social supporter or partner into an SLE-specific 
treatment occurred when Karlson and her colleagues (2004) examined the efficacy of a 
psychoeducational intervention for SLE patients and had them identify and choose one partner, 
either a spouse or a family member, to join them in the intervention. The randomly assigned 
treatment pairs received an intervention designed to increase self-efficacy, communication 
between the pair about SLE, social support, and problem solving. At the 6-month follow-up, 
communication and problem-focused coping improved significantly compared to the control 
group. At the 12-month follow-up, social support, patient self-efficacy, and global mental health 
of the patient had all improved significantly while fatigue of the patient decreased significantly. 
However, global physical function of patients and their disease activity, as measured by the 
systemic lupus activity questionnaire (SLAQ), did not significantly improve over the course of a 
year. The findings provided evidence of some benefits to having a supporter be a part of an 
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intervention but that over time a patient’s physical functioning may not drastically change. 
However, the researchers did not incorporate any disease knowledge component to their study. 
Future studies should incorporate an SLE-specific knowledge questionnaire to assess an 
additional variable related to dyadic relationships.  
Although attempts to educate providers on SLE have not been conducted at this time, 
researchers have found that patients want their doctors to know more. Waldron and colleagues 
(2011) conducted interviews with SLE patients and asked them to recall what their information 
needs were at the time of their diagnosis. The researchers wanted to understand how to improve 
patients’ disease knowledge satisfaction and how to minimize the difficulties associated with 
information gathering. Patients reported feeling that providers were not as accessible as they 
wished and that providers did not inform patients of the “full picture” of what SLE is and how it 
influences life (Waldron et al., 2011). Providers may not be doing all they can to educate newly 
diagnosed patients. This may suggest that providers are not as competent or confident in their 
ability to treat and identify SLE. However, conclusions cannot be substantiated due to the lack of 
information regarding how knowledgeable various medical providers are of SLE. Improved SLE 
education for medical providers could be a way to counteract the negative experiences that 
patients report having with their medical providers (Mak et al., 2009).  
Common Sense Model of Illness 
The Common Sense Model of Illness (CSM) is a theoretical framework that informs 
patients’ experiences living with a chronic illness and how cognitive and emotional factors 
influence coping behaviors and outcomes (Leventhal, Meyer, & Nerenz, 1980). The model 
proposes that a patient’s perceptions about the illness experience influence the overall illness 
representation, coping strategies, and future health outcomes. Patients’ perception their illness 
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and whether they employ positive or negative coping strategies has a direct relationship between 
disease severity and health outcomes (Cameron, 2003).  
There are five components that influence how illness perceptions develop: identity, 
cause, timeline, consequences, and curability/controllability (Hale, Treharne, & Kitan, 2007). 
The identity component labels a condition and the symptoms that are experienced. Having labels 
allows the patient to be able to identify and continue to re-identify the schematic representation 
of their disease. Recurrent symptoms strengthen the labels while new symptoms provide more 
detail regarding the disease. The cause component refers to the individualistic ideas about the 
perceived cause of the condition. The cause can include information gathered from four contexts: 
the biological cause (immune system), emotional cause (stress), environmental cause (pollution) 
and psychological cause (personality or mental state; Hagger & Orbell, 2003; Diefenbach & 
Leventhal, 1996). Information gathered about cause does not necessarily involve factual 
information regarding the cause; instead, these representations are often based on personal 
experiences and information gained through the opinions of others. Significant others, medical 
providers, and the media all influence the individual’s belief about what caused their diagnosis. 
The timeline dimension is the belief about how long the condition may last, 
understanding if an illness is chronic or acute. As the individual adds new details to their illness 
representation patients re-evaluate their timeline representation. The consequence dimension is 
the component of the model that addresses beliefs regarding the impact an illness has on a person 
physically and socially. Only over time does an individual begin to identify accurate beliefs 
rather than irrational ones (Hale, Treharne, & Kitan, 2007). Theoretically, the longer a patient is 
diagnosed with a disease his or her understanding of the disease becomes more accurate. Finally, 
the curability/controllability component addresses the beliefs an individual has regarding 
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whether the condition can be cured and/or controlled (Leventhal, Meyer, & Nerenz, 1980). This 
involves understandings of treatment options and the effects of treatments (i.e., management vs. 
curable). Information about each of the five CSM components are continuously collected and 
evaluated throughout a patient’s life. Providing opportunities to give patients accurate SLE 
information could aid in the process of re-evaluating inaccurate illness representations and create 
a new more accurate representation based on accurate knowledge.  
According to the CSM, information is gathered in three different ways. The first is 
through general or layperson information gained from previous social communication and 
cultural knowledge of the illness. Therefore, individuals who interact with patients need to be 
aware and knowledgeable of the disease because illness representations are partially based off 
the knowledge that individuals around the patient (e.g., community) have of SLE. This means 
that the general public should understand SLE and how it impacts patients. The second is 
information gained from external social environments from significant others or expert sources 
(e.g. doctor). This area of information gathering is important because if experts and significant 
others do not have accurate knowledge of SLE the patient is at an increased risk of being 
exposed to more misinformation. Accurate transmission of knowledge is critical and those who 
are close to a patient need to be accurately informed. The final source of information gathering 
occurs due to the subjective experience of a patient’s illness. Throughout life the illness 
representation evolves (Hale, Treharne, & Kitan, 2007; Leventhal, Meyer, & Nerenz, 1980). 
Patients need to remain informed of their diagnosis and how it will affect them.  
An individual creates a mental representation of his or her illness using concrete and 
abstract information that is gathered throughout the course of the illness. This information is then 
associated with the overall disease experience; this linking of information to the individual’s 
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illness representation is automatic and intrusive (Hagger & Orbell, 2003). As a person 
experiences more intensified symptoms he or she appraises the information gathered to 
determine the level of threat perceived about the illness based on current symptoms. The 
appraisal cycle is what leads to the construction of an illness representation. For example, when 
presenting symptoms activate a negative emotional response (i.e. fear, sadness, worry) the 
symptoms and the association with negativity strengthen the representation that the symptom is 
more dangerous (Cameron, 2003). Ultimately, the more intense an illness is and the more 
symptoms experienced, the more likely a patient is to increase the subjective association of the 
illness being dangerous. If patients believe they have coping skills to combat their negative 
experience, then they can employ these skills. If patients do not believe they have the appropriate 
coping skills, they remain in a high level of distress.  
The CSM theorizes how individuals identify and process information regarding their 
illness, how that information is integrated to provide a representation of their illness, and how to 
employ appropriate coping behaviors (Hagger & Orbell, 2003). As someone obtains new 
information about his or her condition he or she reevaluate their illness representation. By 
improving accurate SLE disease knowledge patients can work to reframe their illness 
representation (Cameron, 2003). Improving the awareness and accurate knowledge of SLE 
among the general public, medical providers and social supporters could be a way to interrupt 
false information transmission to the patient. The more accurate and realistic an illness 
representation is the more likely patients are to utilize appropriate coping behaviors for 
managing SLE (e.g. seeking medical care, avoiding risky behaviors), which improves disease 
experience and QoL. Therefore, it is important for a patient’s illness representation to be 
informed by accurate knowledge. 
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Implications for Knowledge Assessment in SLE 
Having a rare chronic illness has a large impact on a patient’s life. By having an accurate 
understanding and awareness of physical and psychological symptoms of SLE patients’ illness 
experiences could be improved. Increasing knowledge is a way to raise awareness and combat 
negative disease experiences; therefore, assessing SLE knowledge can have implications for 
helping patients, medical providers, and supporters of patients (Hale et al., 2006). The next 
subheadings address why the assessment of accurate SLE knowledge is important.  
Physical Complications. People living with SLE experience a multitude of physical 
symptoms, including but not limited to, inflammation, joint pain, fatigue, skin rashes, and severe 
deterioration of one or several organ systems (Sutanto et al., 2013). Fatigue is most persistent 
and often results in low muscle strength, which is a concern in SLE patients because the muscles 
and joints are at increased risk of deterioration (Parrondo, 2011). Symptoms of SLE do not occur 
independently; rather, they occur together and exacerbate each other. This interaction between 
physical symptoms and the disease progression is important to understand because symptom 
flares vary in severity. Is important for patients to be aware of their limitations when flares are 
severe because disease activity is one of the most predictive factors of patients’ health status 
(Dobkin et al.,1999; Rinaldi et al., 2006).   
The complexity of SLE often leads to a lengthy and daunting diagnostic process. 
Diagnosing SLE requires upwards of 20 tests used in combination and it is common to take up to 
5 or more years to receive a diagnosis (Lam & Petri, 2005; NIAMS, 2008). The American 
College of Rheumatology developed the 11 diagnostic criteria for diagnosing SLE (Hochberg, 
1997). The individual must exhibit at least four criteria, at least one medical test confirmation 
and one affected organ system. The diagnostic categories include rashes (malar or discord), 
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photosensitivity, mouth sores, arthritic symptoms, lung/heart inflammation, renal disorder, 
neurological disorder, hematologic disorder, immunological disorder, and a positive Antinuclear 
Antibody (ANA) test. There is no cure for SLE and the progressive style of disease activity is 
serious. The longer patients go without receiving a diagnosis, the longer they go without the 
appropriate treatments (Lau & Mak, 2009). Improving knowledge of SLE symptoms among 
those at higher risk for SLE could lead to an earlier diagnosis because individuals could identify 
symptoms earlier and see out the appropriate care. Additionally, improving medical providers’ 
knowledge of SLE symptoms could lead to an earlier diagnosis window for future patients 
because they would be aware of the combination of symptoms that constitute an SLE diagnosis.  
SLE is referred to as “the great imitator” because of the way that symptoms mimic a 
variety of other chronic illnesses, such as rheumatoid arthritis, fibromyalgia, hypothyroidism, 
multiple sclerosis, and more general dermatology disorders, endocrine system dysfunctions, and 
infections (Sutanto et al., 2013; Benseler & Silverman, 2007; NIAMS, 2008; Cojocaru, 
Cojocaru, Silosi, & Vrabie, 2001). It is critical for patients to know that as their overactive 
immune system continues to attacks various healthy organ systems they are at an increased risk 
of a variety of additional life-threatening comorbid diseases (Pons-Estel et al., 2010). People 
living with SLE are at increased risk for pulmonary, cardiac, gastrointestinal, ocular, 
hematologic and neuropsychiatric disorders (Parrondo, 2011). The physical complications of 
SLE go through ebbs and flows and the risk of comorbid diseases is high. Being aware of the 
complications that symptoms present is important to help patients manage their SLE daily.  
Psychological Complications. Danoff-Burg and Friedberg (2009) assessed the 
satisfaction of patients’ needs and found that 91% of their SLE sample reported a psychological 
need being unmet. Not only do patients’ needs remain unmet, but they also experience a general 
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negative affect and are more susceptible to psychological distress, such as additional stress and 
worry (Moses, Wiggers, Nicholas, & Cockburn, 2005). The increase of distress and 
dissatisfaction lead individuals to be at an increased risk of more severe mental health concerns, 
which, in turn, exacerbate disease activity. Nery and colleagues (2007) reported that life events 
contribute to the onset, recurrence, and severity of depression and that overall psychological 
distress is associated with life events. For example, when life events related to an SLE diagnosis 
are perceived as negative or stressful a patient’s life satisfaction and report of quality of life 
decrease (Bennett, Fuertes, Keitel, & Phillips, 2011; Earnshaw, Quinn, & Park, 2012). The 
nature of SLE continues to influence the mental health of patients far beyond the diagnosis.   
Comorbid psychological disorders occur more often in SLE patients compared to the 
general public. Mood disorders such as major depressive disorder (MDD; single episode and 
recurrent episodes), depression due to a general medical condition, and depressive episodes not 
otherwise specified (NOS) have been reported in up to 69% of SLE patients (Nery et al., 2008). 
MDD, is in fact, the most diagnosed disorder for patients with SLE; the lifetime prevalence rate 
has been estimated to be 49.2% (Kozora, Ellison, & West, 2006; Nery et al., 2008; Stojanovich, 
Zandman-Goddard, Pavlovich, & Sikanich, 2007; Julian et al., 2009; Nery et al., 2007). 
However, the national average for receiving an MDD diagnosis in life is only 20.8% (Kessler et 
al., 2005). Unfortunately, providers and patients often times attribute depressive feelings to a 
general low mood and do not take the necessary precautions to help manage the true severity of 
depression (Giffords, 2003).  
Disease activity has a direct relationship to psychological symptoms because as a 
patient’s disease severity increases their reports of anxiety symptoms increase as well (Bachen, 
Chesney, & Criswell, 2009). Anxiety is another common psychological concern for SLE 
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patients, with a lifetime prevalence rate being as high as 52% (Meszaros, Perl, & Faraone, 2012; 
Bachen et al., 2009; Nery et al., 2008; Stojanovich et al., 2007; Beckerman et al., 2011). 
However, lifetime prevalence of anxiety disorders in the general population is lower at 28.8% 
(Kessler et al., 2005). In a large all female sample only 4.3% of the sample met diagnostic 
criteria for generalized anxiety disorder (GAD) at the time of the study (Bachen et al., 2009). 
Many factors go into having a current GAD diagnosis and just because someone does not meet 
the necessary criteria to receive a formal diagnosis does not mean the level of worry and anxious 
feelings experienced do not negatively impact the patients’ life. Instead, some level of anxiety 
related diagnosis is experienced at a relatively high rate. Anxiety-related disorders such as 
specific phobia (24%), panic disorder (16%), and obsessive-compulsive disorder (9%) were also 
diagnosed in SLE patients at a significantly higher rate than the general population sample 
(Bachen et al., 2009). Although the specific diagnosis may vary across patients, the rate of 
anxiety and anxiety-related disorders is severely elevated in this disease population. 
Psychosis is also a serious concern for SLE patients. It is diagnosed in 2-3% of SLE 
patients but as high as 31-39% for those on high doses of corticosteroids (Pego-Reigosa & 
Isenberg, 2008). Long-term corticosteroid medication use has adverse effects on hippocampus 
receptors which have been found to directly cause hallucinations and paranoia (Nery et al., 2008; 
Mak et al., 2009). Corticosteroids are one of the more dangerous treatment medications that are 
used intermediately for patients throughout the course of their life. Due to the high toxicity, the 
recommendation is that any steroid medication should be used in the lowest dose possible, for 
the shortest amount of time that results in disease management (Chatham & Kimberly, 2001). 
Corticosteroids minimize the progression of autoantibodies that attack the healthy cells and 
decrease inflammation; therefore, patients who experience more severe flares, cutaneous skin 
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lesions, advanced SLE lung disease, renal disease, and severe inflammation are prescribed 
steroid medications (Chatham & Kimberly, 2001). Even though providers should only prescribe 
corticosteroids in small doses, some patients are prescribed them for substantially longer periods 
of time, which increases patients’ susceptibility to additional medical conditions and increased 
psychological concerns (Chatham & Kimberly, 2001; Pego-Reigosa & Isenberg, 2008).  
Quality of Life. Quality of life (QoL) has been identified as an indicator of the health 
status in patients with chronic diseases (Freire et al., 2011). In general, patients with SLE report 
decreased satisfaction with their lives due to their physical and mental health concerns. Those 
with more severe SLE report worsened physical health and have decreased social interactions, 
which leads to less supportive relationships (Panopalis & Clarke, 2006; Dobkin et al., 1999). 
Patients variability in their physical (e.g. increased symptom severity/flares), mental (e.g. general 
low affect and psychiatric disorders), and social (e.g. relationships with physicians) experiences 
place these patients at increase susceptibility of lower QoL. Compared to the average American 
adult, SLE patients are functioning at a lower level than non-diagnosed individuals (Pons-Estel et 
al., 2010). For individuals living with chronic illness, QoL is critical. Their life is often 
interrupted by their disease. For patients living with SLE, their experiences are so unique that 
they are susceptible to additional factors that threaten their QoL (Yazdany, 2011). Factors 
influencing SLE-QoL, include age, duration of illness, amount of education, self-efficacy, 
knowledge of lupus, and social support (Thumboo & Strand, 2007; McElhone et al., 2007).  
Stigmatization. The invisibility of SLE increases patients’ daily stress level because they 
can experience isolation and stigmatization from the public, medical providers, and even their 
social support networks (Hale et al., 2006; Kool & Greene, 2012; Kool et al., 2010). Feelings of 
anticipated stigma, fears of rejection, increased self-consciousness, and reports of guilt regarding 
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their diagnosis are common for someone living with SLE (Earnshaw et al., 2012; Sutanto et al., 
2013). Patients’ experiences with negative social interactions increase their stress levels and lead 
to perceptions of less support. Patients report that when individuals such as friends, family, and 
work colleagues do not fully understand their disease they feel stigmatized for their experiences, 
which perpetuates their distress (Hale et al., 2006; Earnshaw et al., 2012). Feeling misunderstood 
causes more distress and is associated with decreased mental and physical health of SLE patients 
(Dobkin, et al., 1998). 
Another source of increased worry that patients feel is related to the self-conscious 
feelings experienced when visiting physicians (Beckerman et al., 2011). Patients have reported 
that they worry about physicians judging them during their medical appointments and these 
worries increase when patients believe their doctors perceive them as uneducated. SLE is 
diagnosed more in individuals who are from lower SES populations and this increased distress of 
stigmatization because of low education has a major impact on patients’ perceptions of 
themselves. This stigma worry is an additional barrier for SLE patients when it comes to seeking 
appropriate medical care (Feldman et al., 2013). Patients express concern that they do not want 
to look bad in front of their health care professionals and if they perceive their provider is likely 
to stigmatize them, they are likely to avoid going.  
Medication Adherence. When SLE is not managed properly, disease activity and 
complications increase (Lau & Mak, 2009). Medication use is the most common treatment for 
SLE because of the direct biological influence. Medication non-adherence is also a contributor to 
the increased health care cost of SLE (Lau & Mak, 2009). As disease activity increases so does 
the cost of care for an individual with SLE, this often relates to the necessary hospitalization 
stays that are often required when disease activity is severe (Holloway et al., 2014). Non-
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adherence rates in patients are as high as 76% which can be extremely dangerous for a patient’s 
life, both physically and mentally (Costedoat-Chalumeau et al., 2013).  
Patient’s knowledge of treatment options and his or her belief of the necessity for correct 
adherence has also been associated with higher non-adherence rates (Costedoat-Chalumeau et 
al., 2013; Chambers, Raine, Rahman, & Isenberg, 2009). Increased psychological distress, most 
specifically depression, also threatens the consistency and accuracy of medication adherence 
(Marengo et al., 2012; Coleman et al., 2012). Since SLE patients are at higher risk for 
depression, they are inherently more susceptible to poor medication adherence (Julian et al., 
2009). Additionally, just as patients sometimes avoid doctor appointments when they feel that 
their physician judges them, poor rapport with a provider also plays a role in the individual’s 
non-adherence. If a patient feels unheard and disregarded by their provider, they are less likely to 
inform their physicians of new or worsening symptoms (Sutanto et al., 2013). Increased rates of 
psychological distress, poor physician relationships and a lack of information regarding the 
importance of accurate medication use all can contribute to poor medication adherence.  
Benefits of Disease-Specific Questionnaires 
Previous researchers have explored the importance of assessing specific disease 
knowledge. Through more focused assessments of disease knowledge researchers are better able 
to understand levels of knowledge among various groups. Specifically, these research designs 
provide opportunities to assess what knowledge patients do or do not have, what medical 
providers know and where gaps of knowledge exist, and assess the level of knowledge that 
family and friends and the general public have of the disease. Further examination of disease 
knowledge could be a way to increase knowledge and awareness of SLE while concurrently 
decreasing stigmatization. Since no SLE-specific knowledge questionnaire exists, understanding 
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how other disease-specific knowledge questionnaires have been designed and implemented is 
informative to understand the process that developing an SLE-specific questionnaire would take.  
 Carpenter and colleagues (2009) created a new and valid general knowledge 
questionnaire to assess Alzheimer’s disease (AD) knowledge. They developed a pool of 
questions that were previously used in other measures to assess AD knowledge within patient, 
professional, and community samples. This provided the researchers the opportunity to gather a 
wide range of items for the new questionnaire, which consisted of questions targeting risk 
factors, assessment and diagnosis, symptoms, course, life impact, caregiving and treatment. The 
final product consisted of true/false items that allowed for a short and quick questionnaire. 
Knowledge was significantly higher for those who had attended a support group for dementia 
and for those who worked with patients with dementia than those who had not, those who were 
college students or those who worked in a senior center (Carpenter, Balsis, Otilngam, Hanson, & 
Gatz, 2009). Findings suggest that there are group differences in disease knowledge given an 
individual’s awareness of AD. Specifically, the more personal experience and awareness that 
participants had was reflected in their AD knowledge.  
Another example of assessing disease-specific knowledge is for diabetes-specific 
knowledge questionnaires. Multiple diabetes knowledge questionnaires have been developed and 
tested. Fitzgerald and colleagues (1998) examined the reliability and validity of a brief diabetes 
knowledge test while other researchers have created and examined alternative measurement tools 
(e.g. Revised Diabetes Knowledge scale; Collins, Mughal, Barnett, Fitgerald, & Lloyd, 2010).  
Fitzgerald and colleagues (1998) compared patient scores that were collected from two different 
medical centers. They determined that there were differences among scores depending on the 
medical setting and patient populations and there was a degree of variability between groups. 
 
 
20	
	
Collins et al. (2010) additionally compared the effects that different response formats could have 
on scores. The new measure was adapted to have binary responses based on the multiple-choice 
items found on the Simplified Diabetes Knowledge Scale. Results indicated that average scores 
were remarkably similar (62% (multiple choice) compared to 65% (true/false)). The responses 
style does not seem to affect the outcomes when it comes to testing disease-specific knowledge.  
 Many other disease-specific knowledge questionnaires exist, including ones assessing 
STD and HIV knowledge (Carey & Schroder, 2002), heart disease (Bergman, Reeve, Moser, 
Scholl, & Klein, 2011; Wagner, Lacey, Chyun, & Abbott, 2005), chronic obstructive pulmonary 
disease (OCPD; White, Walker, Roberts, Kalisky, & White, 2006), cystic fibrosis (Siklosi, 
Gallagher, & McKone, 2010), multiple sclerosis (Giordano et al., 2010), fibromyalgia (Suda, 
Jennings, Bueno, & Natour, 2012), osteoporosis (Winzenberg, Oldenburg, Frendin, & Jones, 
2003) and arthritis (Edworthy, Devins, & Watson, 1995). Researchers have also conducted 
studies to examine the level of knowledge that different groups have. Disease-specific 
knowledge questionnaires have been used in various disease populations and have been used in 
conjunction with additional educational intervention material to improve the awareness that 
patient populations and significant others have of various diseases.  
Purpose of Proposed Study 
Assessing SLE-knowledge could provide increasingly important benefits to a variety of 
groups by working to reframe the social perspective that others have on this complex invisible 
disease. Creating additional educational material that could be used to improve the knowledge 
that community members have of SLE might help raise awareness of the disease and decrease 
SLE stigma. Improving patients’ knowledge of SLE might encourage them to take a more active 
role in disease management by being aware of disease outcomes. Increasing the knowledge that 
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medical providers have of SLE could help speed up the diagnosis process and improve patients’ 
outcomes. Decreasing the stigmatizing misconceptions of SLE could further improve patients’ 
relations with family, friends and employers. Together, increasing knowledge about SLE could 
help facilitate increased awareness, reductions in stigmatization, and improved patient outcomes.   
 Assessing SLE knowledge in a community sample is the first step in an overall research 
agenda to understand what the level of accurate knowledge and awareness is of SLE. This is the 
first study of its kind to create an SLE-specific knowledge measurement tool in order to assess 
general knowledge of SLE in a community sample. It is the aim of the following proposal to 
develop the first SLE specific knowledge questionnaire and use the questionnaire to explore SLE 
knowledge and the influence of educational exposure and disease proximity. This study involves 
the following research questions and hypotheses: 
RQ1) What are the common topics that providers identified as being important to be 
included in the Lupus Knowledge Questionnaire?  
RQ2) How do participants in a community sample score on the LKQ? 
H1) Individuals with educational exposure of SLE will have higher scores on the 
LKQ than those who have no previous educational exposure to SLE. 
H2) Individuals who have closer disease proximity to SLE will have higher scores 
on the LKQ than those who know no one with SLE.  
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Method 
 
 The current study occurred in four phases guided by adaptations from the questionnaire 
development protocol created by the European Organization for Research and Treatment of 
Cancer (EORTC; Johnson et al., 2011). The protocol had been previously adapted and used by 
researchers to create disease knowledge questionnaires (Jaglarz, Tomaszewski, Kamzol, 
Puskulluoglu, & Krzemieniecki, 2014), quality of life measures (Wheelwright et al., 2013), and 
patient outcome measures (Denniston, Kyte, Calvert, & Burr, 2014; Reeve et al., 2013).  
Phase 1 consisted of interviews with medical experts. Phase 2 incorporated drafting a 
version of the lupus knowledge questionnaire (LKQ); items were created by utilizing qualitative 
methods to analyze interview responses and conducting a thorough literature review of 
educational material used by the Lupus Foundation of American to inform individuals about 
SLE. Phase 3 consisted of the draft version being reviewed for relevance, accuracy, and clarity 
by the same experts who were interviewed during Phase 1. Edits to the LKQ were made based on 
results from a regression analysis and feedback from the providers. Phase 4 concluded the 
proposed study and consisted of two administrations of the LKQ. The first sample was given the 
draft version of the LKQ and a unique second community samples was administered the revised 
version of the LKQ. The samples were used to gather initial psychometric data: internal 
consistency, item analyses (item difficulty/discrimination, readability) and data on participants’ 
LKQ scores. Institutional Review Board approval was obtained from the university to conduct all 
aspects of this study. 
Phase 1: Conducting Provider Interviews  
Participants. Three medical providers (2=MDs; 1= Nurse Practitioner) were recruited to 
consult as experts. Two of the providers were male and one provider was female. Previous 
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researchers recommend using a minimum of two experts to act as consultants to gather 
knowledge data; therefore, the use of three experts was considered adequate (Siklosi et al., 2010; 
White et al., 2006; Jaglarz et al., 2014). In order to participate in the study, the providers needed 
to have previous experience diagnosing, treating and caring for SLE patients. The medical 
providers were recruited from medical centers in Indiana through existing personal and 
professional relationships.  
Procedure. To address Research Question #1, medical providers were asked to complete 
a one-on-one interview to gather qualitative data of relevant SLE knowledge topics. The 
interview protocol was informed by the dimensions of the Common Sense Model of Illness 
because of the focus on disease experience and representation. Interviews are commonly used 
methods used to collect content related to a topic (Gill, Stewart, Treasure, & Chadwick, 2008).  
Measures and Materials. Materials included a hand held recording device and the 
interview protocol. Responses to the interview were recorded to allow for easy reexamination of 
the interview content. Interviews were conducted over the phone and experts were first asked to 
consent to the study before completing the interview. Questions in the semi-structured interview 
protocol included, what resources do you have at your disposal to assist you in providing 
education/knowledge to your SLE patients, what questions regarding SLE do patients not ask 
about that they should, and what should people know about SLE to have a good general 
understanding of the illness and how it is experienced by people? (See Appendix A for Full 
Interview Protocol.) 
Phase 2: Reviewing Patient Education and Interview Data  
Procedure. Previous researches who have created disease-specific knowledge 
questionnaires begin by gathering or adapting a pool of items from previously validated studies 
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that assessed the disease in question (Davis, 1992; Giordano et al., 2010; Carpenter et al., 2009; 
Siklosi et al., 2010). Alternatively, researchers gather general information regarding accurate 
disease information from both literature and expert individuals (e.g., physicians, psychologists, 
nurses, nutritionists; Siklosi et al., 2010; White et al., 2006; Wagner et al., 2005). Given that the 
LKQ is the first of its kind, there were no existing questionnaires to assess. Therefore, only the 
latter method of item creation was used in the current study.  
First, I conducted a literature review to gather information regarding educational 
information on SLE. Secondly, I used the medical providers’ interviews to guide item creation. 
Finally, I assessed materials used by the Lupus Foundation of American to inform patients, 
social supporters, medical providers and the general public regarding SLE.  
A true and false response format with a “don’t know” option was utilized for the LKQ; 
this was a commonly endorsed response style used to develop disease knowledge questionnaires 
(Carpenter et al., 2009; Edworthy, Devins, & Watson, 1995). This option allowed for easier 
administration and more accurate representation of factual knowledge, as compared to a 
multiple-choice design, which is more beneficial for attitude questions (Beatty & Herrmann, 
1995; Poe, Seeman, McLaughlin, Mehl, & Dietz, 1988). When a “don’t know” option does not 
exist participants have reported feeling more compelled to respond without having any basis for 
their answer, resulting in incorrect representations of knowledge. Additionally, including the 
“don’t know” option allowed identification of items that resulted in higher awareness versus 
lower awareness.   
Materials. I used the content from the interviews to inform the initial content of the 
items. Additional support, in terms of wording or more specific details, was gathered through the 
examination of pamphlets developed by the Lupus Foundation of America to educate 
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individuals. Therefore, the materials used to inform the items remained the interviews and the 
pamphlets from the LFA.  
Analyses. Qualitative content methods were used to inform the collection of items on the 
LKQ. I developed a pool of items based off information gathered from the interviews and the 
pamphlet content. Components of directed content analysis as well as standard disease-specific 
knowledge questionnaire methods were utilized to determine the content of the LKQ items. 
Aspects of a directed content analysis were applied because of this method’s focus on being 
informed by an existing theory (Hsieh & Shannon, 2006). Items focused on general knowledge 
of SLE rather than very nuanced aspects of the SLE-disease experience (Johnson et al., 2011; 
Jaglarz et al., 2014; White et al., 2006; Hennell, Brownsell, & Dawson, 2004, & Holloway et al., 
2014). The CSM’s dimensions (identity, cause, time-line, consequences, and curability/ 
controllability) were used to inform the interview questions and items’ final content (Hagger & 
Orbell, 2003; Hale, Treharne, & Kitas, 2007; Potter & Levine-Donnerstein, 1999).  
The initial step of item creation occurred by assessing the broad content areas that the 
providers reported as being important through the interviews. After that, the broad themes were 
described and elaborated on by compiling all the interviewers’ interviews. After this broad step 
was taken the pamphlets were utilized to gather more specific factual information based on the 
providers’ answers. The pamphlets allowed for me to fill in gaps from the interviews. For 
example, the item related to skin rashes was discussed by all three providers and it was covered 
in the pamphlets. Therefore, that item was unanimously supported. Another example is with the 
item that asked if SLE is called the great imitator. For this item, the providers broadly spoke of 
SLE as being difficult to diagnose because it mimics other conditions. However, the pamphlets 
specifically used this verbiage; thus, the pamphlet was used to create the specific item content.  
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Phase 3: Verifying and Revising LKQ Draft  
Participants. The same medical providers from Phase 1 reviewed the LKQ-draft version 
and provided feedback on the relevance of the items as well as provided suggestions on item 
clarity and/or accuracy. Utilizing experts to inform and review disease specific questionnaire is 
commonly used to confirm the content validity of a measure (Johnson et al., 2011; Jaglarz et al., 
2014; White et al., 2006; Hennell, Brownsell, & Dawson, 2004, & Holloway et al., 2014). 
Procedure. Verification and content validity was assessed by having the medical 
providers complete the Content Validity Index (CVI; Beck & Gable, 2001; Polit & Beck, 2006). 
The providers were sent the draft version of the LKQ along with the CVI to rate each item on 
relevance and accuracy. After the providers rated the content and provided feedback, appropriate 
changes were made. For example, if providers gave an item a score of 1 or 2 (see below) and 
provided feedback for the item, that feedback was incorporated and the item was changed to 
make it a highly relevant item. The editing involved correcting the wording of the item and 
increasing clarity of the items based on the additional feedback that the providers left. If an item 
was not considered relevant the providers were asked to give feedback that they believed would 
make that item highly relevant. After all of the providers’ feedback was incorporated the revised 
version was generated. (See Appendix B for the Provider Verification Documents.)  
Measures. The following measures were given to the three medical providers and data 
were used to inform any changes that took place when creating the revised version of the LKQ. 
Content Validity Index Scale. The Content Validity Index Scale (CVI) is a method of 
quantifying content validity based on expert ratings (Polit & Beck, 2006). On the CVI, the 
providers were asked to give feedback on item relevance on a 4 point Likert-type scale (1 = not 
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relevant, 2 = somewhat relevant, 3 = quite relevant, 4 = highly relevant) and provide feedback 
regarding the accuracy and clarity of the medical facts represented in the items.  
Analyses. Scores were calculated based off the CVI procedure. A CVI value was 
computed for each item on the scale (I-CVI). Among the literature there was a lack of clarity 
regarding the specific method that researchers have used to assess each item’s content value 
(Lynn, 1986; Polit & Beck, 2006). For the current study, the method used to calculate the I-CVI 
was conducted by having the relevance scores of each item tabulated into not relevant (ratings of 
1 and 2) and relevant (ratings of 3 or 4). The I-CVI was then computed by summing the three 
scores that each item was awarded and then it was divided by the number of experts (Polit & 
Beck, 2006). However, if a provider gave written clarity or accuracy feedback those edits were 
made and then the item was considered a 4 so that score overrode the score of one or two. (See 
Appendix D for CVI verification feedback) 
Lupus Knowledge Questionnaire-Draft (LKQ). The draft version of the LKQ was sent to 
the providers and consisted of 38 items related to central domains of SLE knowledge. The items 
were informed by the theoretical framework outlined by the CSM and the item content was 
gathered from a literature review of patient education material and medical provider interviews. 
Items were created with a True/False and “don’t know” structure. Each item was assessed by the 
three medical providers. (See Appendix E for the LKQ items in the CSM dimensions.) 
Phase 4: Testing the LKQ and the LKQ-R 
Participants. The final phase of the current study consisted of two full-scale 
administrations of the LKQ. The draft-LKQ was first distributed to a sample size of 336 
participants. Of those, 192 identified as female (57.1%) and the majority of the sample identified 
as Caucasian/White (N = 278; 82.7%). The mean age was 21.5 (SD=1.82) with ages ranging 
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from 18 to 24 years old. Just over half of the sample was enrolled in college in some capacity, 
part-time (N=21; 6.3%) or full-time (N=165; 49.1%; Table 1: Frequency of Demographic 
Variables).  
The LKQ-R was distributed to a second independent community sample of 241 
participants. There were a total of 237 participants who participated in the second administration 
of the revised LKQ. However, fewer participants’ data were used for the final analyses. One of 
the many edits made to the LKQ-R was to include a validity item (item 20: Please answer “true” 
for this item). After initial demographic data were collected and analyzed 49 participants 
incorrectly answered the validity question by choosing doesn’t know rather than true. Therefore, 
those 49 individuals’ data were excluded from the remaining analyses. Additionally, four 
individuals did not provide an answer at all. In order to treat the validity item as intended, these 
four individuals were also excluded. The final sample size for the second administration was 188 
participants.  
Of the included participants, the majority were female (N=144, 76.7%). The average age 
of the participants was 33 (SD=6.11) and ages ranged from 20 to 54 years old. Most of the 
sample identified as Caucasian/White (N = 154; 83.2%) and followed by African American 
(N=10, 5.4%). Approximately ¾ of the participants were married (N=173, 73.3%). The Average 
years of education was 15.6 (SD=2.24; see table 8 for Frequency of Demographic Variables).  
Procedure. The same procedure was used to recruit participants from both community 
samples. Participants were recruited by students who were enrolled in a combined undergraduate 
and graduate psychology course to participate in an online survey through surveymonkey.com. 
As a course requirement, students had to recruit participants through the use of a snowball 
sampling method such that each study approached at least one possible participant and asked that 
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participant to identify at least one more potential participants and so on (Patton, 1990). Students 
in an advanced psychology laboratory class recruited eight English-speaking community 
members to complete the online survey. All students involved in data collection were required to 
complete training in the ethical conduct of research and alternative assignments were provided to 
reduce the likelihood of data fabrication. Parents provided informed consent prior to completing 
the full survey. The first sample consisted of young adults and they had to be between age 18 to 
24. The second sample consisted of adults who had to be a parent. Class research credit was 
given to the students for recruiting effort and students were not penalized for failing to recruit the 
required number of participants. The participants completed a battery of questionnaires aside 
from the current studies’ measures. The data collected for the current study were collected as part 
of a larger data collection project; thus, other studies’ data were collected concurrently. For this 
study the data gathered from both samples included informed consent, demographic survey 
items, perceptions of knowledge items, disease proximity and educational exposure items, and 
the appropriate LKQ version. 
Measures. Participants from both samples were asked to complete the following 
measures. The first sample completed the draft version of the LKQ and the second sample 
completed the revised version of the LKQ:  
Demographics. The items included asked participants about their age, race/ ethnicity, 
level of education, and marital status. (See Appendix C for Demographic Questions.)  
Disease Proximity to SLE. Participants were asked to indicate their relation to SLE based 
on four yes/no items meant to assess disease proximity. The disease proximity items were used 
to determine whether the individual had close proximity to SLE due to personally being 
diagnosed with SLE, having immediate family members diagnosed, extended family family 
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diagnosed, or if they knew anyone else with SLE. Participants were offered the option to skip the 
disease proximity items with the assurance that they would not be penalized. If participants 
answered “yes” to having known a family member (immediate or extended) or another person 
with SLE they were also asked to provide a description of their relation to the participant (ex. 
Cousin, friend, co-worker; See Appendix C for Disease Proximity Items).  
For the purposes of analysis, due to the overlap of endorsed proximity, I had to categorize 
the groups as the following: group 1 consisted of people who reported having personal SLE 
and/or knew a family member (immediate and/or extended) with SLE; group 2 consisted of 
participants who indicated knowing someone else with SLE; group 3 consisted of people who 
reported having none of the above proximities to SLE. Due to the low number of individuals 
who reported personally having SLE or reported having a family member diagnosed with SLE, 
those individuals who did endorse that item were automatically placed into group 1. This 
occurred regardless of any additional endorsement of knowing someone else with SLE. Those 
individuals who were in group 2, only endorsed knowing someone else. Therefore, having a 
closer proximity meant a participant’s data were used within that closer proximity group. 
Educational Exposure to SLE. Participants were also asked to indicate their educational 
exposure to SLE based on four yes/no items meant to assess their exposure to SLE-disease 
information that they gathered through a learning related environment. The educational exposure 
items included questions related to whether the participant had heard of SLE, had they attended a 
lecture on SLE, had they learned about SLE in a class, and had they read about SLE. (See 
Appendix C for Educational Exposure Items).  
For the purposes of analysis, to determine groups for the educational exposure groups 
participants were similarly imposed into the various groups. I had to categorize the groups as the 
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following: group 1 consisted of people who reported having heard of SLE; group 2 consisted of 
participants who indicated having read about SLE, learning about SLE in a class, and/or 
attending a lecture on SLE; group 3 consisted of people who reported having none of the above 
exposures to SLE. Due to the low number of individuals who reported having a deeper 
educational exposure to SLE, those individuals who did endorse that item were automatically 
placed into group 2. This occurred regardless of any additional endorsement of hearing about 
SLE. Those individuals who were in group 1, only endorsed having heard of SLE. Therefore, 
having a deeper educational experience meant a participant’s data were used within that deeper 
educational group. 
Perception of Knowledge. Participants were asked to rate their perceived level of 
knowledge before and after taking the knowledge questionnaire. Prior to the participants 
completing the LKQ they were asked to rate how confident they were about their knowledge of 
SLE (1= Not Confident, 5= Extremely Confident). After participants completed the LKQ they 
were asked to report their perceived score on the LKQ (0-100%) as well as how well they 
perceived their knowledge of lupus to compare to the average person (1= I have more knowledge 
than the average person, 5= I know nothing compared to the average person; See Appendix C).  
Lupus Knowledge Questionnaire-Draft (LKQ). The draft version of the LKQ that was 
administered to the first community sample consisted of 38 items related to the central domains 
of lupus knowledge identified during the phases of questionnaire development. Items were 
created with a True/False and “don’t know” structure (see Appendix F for Draft Version).  
Lupus Knowledge Questionnaire-Revised (LKQ-R). The revised version of the LKQ 
was created after data was gathered from the initial sample of participants and the CVI feedback 
was incorporated. The edited version consisted of 34 items related to the central domains of 
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lupus knowledge identified during the phases of questionnaire development. Items remained in 
the True/False and “don’t know” structure. The LKQ-R was used in the second administration of 
Phase 4 (see Appendix G for Revised Version).  
Analyses.  The same analyses were conducted for both samples, except that item 
discrimination was also conducted for the second sample. Participants completed the survey 
through an online link and following data collection all responses were entered and analyzed in 
the Statistical Package for the Social Science (SPSS) version 19 software (IBM Corp., 2010).  
Descriptive statistics including frequencies, percentages, and measures of central tendencies 
were calculated for survey items and demographic items. An alpha level of 0.05 was set to 
determine the level of statistical significant.  
Kruskal-Wallis One-Way ANOVA. The Kruskal-Wallis one-way analysis is used to 
determine whether three or more nominal groups (e.g., close proximity, other proximity, 
none/heard of SLE, deeper educational exposure, none) are the same or different on some 
continuous variable of interest (e.g., scores on the LKQ or LKQ-R; Chan & Walmsley, 1997). In 
order to assess any differences between educational exposure and disease proximity groups 
across the LKQ the standard One-Way ANOVA analyses could not be completed because the 
data were not normally distributed; therefore, this nonparametric equivalent was utilized. The 
KW ranks each groups’ median score on the continuous variable (LKQ scores); thus, the groups 
are ranked in order and it is provided in a mean rank ordering. Two very important advantages of 
ranking data (i.e., conducting a Kruskal-Wallis) instead of using the original data are (1) the 
calculations are simple and (2) few assumptions are made about the kind of distributions.  
Internal Consistency. Internal consistency indicates how well the items on a measure fit 
together conceptually and ensures the level of consistency of answers item by item (Terwee et 
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al., 2007; Clark & Watson, 1995). The Kuder Richardson-20 Formula was used due to researcher 
agreement that it is a more appropriate statistical method to calculate dichotomous items 
(Wagner et al., 2005). Score values of the Kuder Richardson-20 range from 0.0 to 1.0, where a 
score of .70 is the low end of an acceptable score (DeVellis, 2003).  
Split-Half Reliability. A second internal consistency measure was also calculated. A split-
half reliability assesses the internal consistency of a test, by dividing the scale into two equal 
parts to test equally what is being measured (Crocker & Algina, 1986). Each half of the measure 
receives a Pearson r score, ranging from -1.00 to 1.00 and then each half is compared to one 
another. Therefore, another internal consistency score was reported: Spearman-Brown 
coefficient. The measurement procedure is considered to demonstrate split-half reliability if the 
two sets of scores are highly correlated (DeVon et al., 2007).  
Item difficulty. A full range of responses is important for a novel questionnaire and those 
items that have limited discrepancy should be excluded. In particular, floor and ceiling effects 
should be examined based on item distribution (Johnson et al., 2011). The item difficulty 
analysis is conducted by dividing the number of individuals who responded correctly by the 
number of total respondents. The scores are then used to identify items that are answered 
correctly by more than 80% (too easy) or fewer than 20% (too difficult; Wollack, n.d; Carpenter, 
et al., 2009). Values are used to assess item difficulty, values range from 0.00 to 1.00 and values 
closer to 0.00 are considered more difficult (Sim & Rasiah, 2006). It is optimal to have a 
difficulty level of .75 when there are two options for a test (McCowan & McCowan, 1999). 
However, scores between .30 and .80 are considered acceptable.  
Item discrimination. The item discrimination index is a measure of how well an item 
distinguishes between respondents who are knowledgeable and those who are not (Wollack, n,d). 
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This statistic measures the differences between the percentage of participants in the lower and 
upper 27% of scorers who score correctly (Sim & Rasiah, 2006). Scores range from -1.0 to 1.0 
and converted into a percentage. The higher the discrimination index the better the item can 
determine the difference between participants who score high and those who score low on the 
questionnaire (Sim & Rasiah, 2006). Scores of 0.4 and higher are considered desirable items and 
a minimum of 0.2 has been proposed as the cutoff value below at which items should be 
discarded (McCowan & McCowan, 1999).   
Readability. All instruments used to educate individuals should not exceed a ninth grade 
reading level; however, readability scores often exceed the ninth grade level (Rudd, Moeykens, 
& Colton, 1999). Not exceeding a ninth grade level helps to ensure that questions can be 
understood by a wider range of readers (Terwee et al., 2007). There are a variety of readability 
analyses, but there is controversy about which to use because some analyses have been found to 
produce different scores for the same material (Calderon, Morales, Liu, & Hays, 2006; Friedman 
& Hoffman-Goetz, 2006). For the current study, readability was assessed through two common 
measures. The Flesch-Kincaid Readability formula (FRF), which provides a grade reading level 
score (Kincaid, Fishburne, Rogers, & Chissom, 1975). This assesses the readability of text based 
on the number of syllables per word and words per sentence (Young, et al., 2002). The Flesch 
Reading Ease Scale (FRES) provides an age appropriate reading level. Both scores are calculated 
by using computer software in Microsoft Word (Coleman & Liau, 1975; Rhee, Von Feldt, 
Schumacher, & Merkel, 2013).  
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Results 
Phase 1: Conducting Provider Interviews 
 The interviews conducted were informed by a set of items designed to represent relevant 
SLE knowledge domains. Three medical providers were enrolled. The interviews took 55 
minutes, 38 minutes, and 1 hours and 5 minutes, respectively.  
 The qualitative data presented encompass the interview data gathered from the first and 
third sets of protocol questions (Appendix A).  Data gathered during the second set of questions 
were not relevant to the creation of the questionnaire because the purpose of set two was to 
determine whether any SLE-specific questionnaire tools were used by the providers. They all 
reported that no such tool existed. Under set one, I will report on the SLE-specific content that 
the providers gave regarding information informed by the Common Sense Model of Illness, A) 
cause, B) identity, C) timeline, D) controllability, E) consequences. For the third set of interview 
items, I will briefly present data that the providers reiterated and added with regard to educating 
others.  
Research Question 1. What are the common topics that providers identified as being 
important to be included in the Lupus Knowledge Questionnaire? 
Interview Set One: Common Sense Model of Illness. Providers were asked to provide 
detailed topics, themes, or general facts that related to the five dimensions of the CSM. Some of 
the dimensions proved to be more difficult to provide facts or explicit concepts on due to the 
dimension not having one or a simple straight forward answer. This problem was identified 
throughout the interviews and it attributed to the fact that SLE is not predictable and patients 
experience different disease expressions (physical complications, internal organ system 
involvement) and severity of disease (flares; mild or severe). Nevertheless, results below 
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describe the range of topics that the providers give in an attempt to report clear and factual 
information. 
Cause. The providers reported that understanding the cause of SLE requires an awareness 
of broad and narrow facts. Broadly speaking, providers reported that the cause of SLE is not 
fully understood. They reported knowing about risk factors but ultimately reported that it is 
difficult to identify each person’s triggers or reason for the disease onset. This is why patients 
should be aware of the three categories of SLE cause. These include the involvement of genetics, 
environmental hazards, and hormones all of which are areas that the medical community has 
linked to SLE onset.  
Beginning with genes, providers mentioned that a person has a genetic predisposition for 
SLE prior to the disease actually showing symptoms. For the onset to occur individuals who 
have the various genetic sequences and linkages for SLE must come in contact with an 
environmental “trigger” which then activates the mutation and the signs and symptoms begin 
expressing. Scientists have identified these genetic aspects of SLE. However, it is much more 
difficult to identify which of the environmental or hormonal triggers initiated the disease 
expression and there are no fail-proof ways of assessing what trigger will cause or has caused 
each case of SLE to activate. Nevertheless, factors that have been linked to the onset of SLE 
were increased exposure to sunlight, direct exposure to various hazardous chemicals, pregnancy, 
and increased life stress. Hereditability is important to understand because it can allow for 
someone to be aware that they have or may have the genetic predisposition for SLE.  
Identity/Symptoms. The providers’ discussions regarding symptoms unanimously 
supported the notion that patients need to know that the general severity of symptoms vary. Just 
as the specific triggers are hard to identify for each individual patient, each person’s experience 
 
 
37	
	
with symptom expression and severity are often unique to him or her. It was reiterated that being 
aware that the intensity of symptom expression can help patients learn to manage their disease 
better. Although severity may vary, many symptoms are quite similar. The providers included 
both visible and invisible symptoms, but highlighted the increased number of invisible symptoms 
that patients experience.  
The providers mentioned the chronic symptoms of SLE and how more flares occur but 
many internal symptoms can only be identified by test results. The providers emphasized the 
extreme fatigue and chronic stiffness and joint pain that occurs. These symptoms were discussed 
as the first indicators of rheumatologic conditions but the symptoms are often disregard by 
patients and providers. Patients tend to wait to seek answers because they attribute their tiredness 
and soreness to other stressors, concerns, or conditions. One provider mentioned that he tends to 
see patients once the accumulation of symptoms already occurs. These include weight gain or 
loss, hair loss, loss of circulation in the hands (causes the hands to take on a blue tint), facial skin 
rashes, digestive system issues, and increased feelings of depression. These symptoms are also 
often missed by medical providers because they can be common in other conditions.  
The final set of symptoms that the providers discussed were the medical tests used to 
confirm an SLE diagnosis. They named some commonly used diagnosis tests, which included 
the antinuclear antibodies (ANA), platelet count, antibodies to double-strand DNA (anti-dna), 
and antibodies to phospholipids (aPLs). These tests are not often run until a multitude of other 
conditions have been ruled out. For instance, the ANA is the most commonly used diagnostic 
test. However, its scores can become elevated for other reasons, thus, a high rate of false 
positives and false negatives occur for patients. Therefore, a combination of these various 
antibody tests and blood draws need to be run to gather enough data to confirm a diagnosis.  
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In order to have a diagnosis of SLE, a patient must have a combination of the physical 
symptoms and medical test results. The providers highlighted how important it is that patients 
tell their doctor when they experience any physical symptoms. One provider mentioned that he 
hopes patients always hold their own feelings in high regard and express to their providers when 
they feel “off” because patients are the best reporters of their own experiences. He believed that 
patients are ignored by their physicians too often. Therefore, in order to identify symptoms early 
and begin treatment patients must be an active reporter of their experiences.  
Course/Timeline. It is important for patients to understand that this is a chronic disease 
and they will have it forever, but their life does not end when they receive a diagnosis. The 
providers reiterated that patients need to understand that the diagnostic process is lengthy and the 
timeline to receive a diagnosis varies greatly. However, two of the providers reported that they 
are much more familiar with various SLE signs and symptoms than other medical professionals; 
therefore, they are able to diagnose the patient earlier. They reported that many other providers 
not familiar with SLE do not pay much enough attention to the accumulation of symptoms and 
end up writing their patients off. All three reported this as a common concern and reason for why 
the process of receiving the diagnosis is so lengthy.  
As a rheumatologist, one provider receives referrals for recently diagnosed patients. He 
reported having different objectives when it comes to considering an SLE timeline. His concerns 
involve understanding how long the disease had been present prior to the official diagnosis 
because that timeline is critical for understanding the amount of damage that has occurred. 
Knowing those details informs him about what the appropriate medication regimen involves. The 
earlier the treatments can begin the less damage occurs in the body. There is no “one rule fits all” 
when it comes to diagnosing and treating.  
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Controllability/Curability. The providers unanimously agreed that patients need to 
understand that SLE is not a death sentence. The providers reported optimism in current 
treatments and highlighted how the disease can be managed with treatments. In order to control 
SLE, patients must know their body and how their day-to-day activities influence how they 
experience their SLE. For instance, paying attention to symptoms is critical for helping control 
the ebbs and flows of symptom severity. One day a patient may feel very healthy while the next 
they may feel extremely sick. In order to better control their SLE patients must alter their 
lifestyle to ensure they do not exert themselves too much.  
 Medications have been adapted over the last 20 years and the providers reported that they 
have positive effects when taken correctly and consistently. Patients must understand how 
important it is to know their medications and understand that some medications (e.g., steroids) 
have quite harmful long term effects while other medications (e.g., anti-inflammatories) are 
taken daily to ease aches and pains. Ensuring accurate adherence will help minimize severe 
flares. SLE can be managed by medications but receiving the appropriate dosage is a process that 
requires patient-provider collaboration and teamwork.  Additionally, it is important that patients 
understand that SLE is not contagious. The fear of giving it to another person is a common 
misconception.  
Consequences. The providers were asked to discuss how an SLE diagnosis influences a 
patient’s life: socially, physically, and mentally. The providers elaborated that the majority of 
their previous and current patients express a concern about the ability to “maintain their previous 
life.” Patients do not want to feel limited by their diagnosis and so learning how to manage their 
disease is beneficial and helps patients become more optimistic. Increasing social support helps 
increase optimism, as does learning to monitor one’s physical and mental experiences. Co-
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morbid diagnoses of depression and/or anxiety after receiving an SLE diagnosis are common and 
contribute to the shift in patient’s lives. 
The providers mentioned how patients are often scared and confused by their diagnosis 
and tend to believe that they cannot maintain their physical lifestyle. The providers agreed that 
when a patient manages their SLE and participates in their treatments their life does not need to 
change dramatically. However, they do warn that because of the variability of symptom severity 
neither they nor a patient can be sure what each day will look like. Therefore, caution must be 
taken. Even more, many patients with SLE often end up being unable to work.  
To ensure that a patient’s SLE is managed, he or she must monitor their lifestyle. 
Common topics related to lifestyle management included maintaining a moderately active 
lifestyle (e.g., nonaerobic), incorporating healthy diet (e.g., minimize meat and gluten), minimize 
prolonged sun exposure, no smoking, and correct medication management. Looking towards 
one’s future and being aware of his or her increased risk of comorbid diagnoses is an additional 
reason that proper lifestyle management needs to occur. Prolonged SLE consequences are quite 
severe and include neurological concerns (e.g., memory), digestion issues, cardiovascular health, 
and circulatory function.  
Interview Set Three: Additional Information for Others. During set three, providers 
were asked to report on what information related to SLE was important for other people (e.g., 
family, friends, social supports, general public) to know. The goal was not only to gain 
information about SLE facts relevant for patients but also to know if additional aspects of SLE 
knowledge were important for others to know about SLE. The emphasis in this section was to 
encourage the providers to give any reiteration of themes already mentioned and to allow for 
further elaboration.  
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General Information for Others. Overall, the providers reiterated many similar themes 
that they had mentioned during set one. The providers discussed that a portion of distress patients 
experience occurs because of others being misinformed and uneducated about SLE. Therefore, it 
is important to help educate family and supporters about SLE. Providers discussed noticing that 
those who interact with patients are just as scared and confused as patients are of the 
complexities of SLE. Increasing awareness of SLE and how it is experienced might be the first 
step in helping create an educated support network for patients.  
Specific for Family. When it comes to educating the family members, it is more important 
to understand who the patient wants involved in their care rather than presuming who is 
important to inform. This is because support is not unidimensional and patients may bring their 
spouse, child, parent, or friend with to a doctor’s appointment. Thus, increasing the awareness 
and knowledge that those individuals have of SLE should take priority. This is important to 
understand because these support individuals are in the appointment with patients when the 
doctor explains any concerns or results. That supporter should be able to remain active and 
involved in the appointment alongside the patient. This means having a thorough understanding 
of SLE. This is an additional way to encourage better collaborative communication between all 
parties. One provider said that he believes patients have so much on their mind that having an 
informed supporter with them is essential. 
Two phrases that the providers mentioned as being unwarranted misconceptions about 
SLE were “it’s all in their head” and “…but you look fine.” These two phrases relate to the 
invisibility of SLE and therefore other people are unable to see the effects of SLE. SLE is a 
disease and it is not “in their head.” If SLE manifested on the outward appearance people might 
begin to understand how detrimental it is on the person. However, because people cannot see the 
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internal deterioration of SLE they use this phrase. Phrases such as these belittle and minimize the 
realities of SLE. Patients need to know that these phrases are false and it is equally important that 
family and the public understand that although symptoms are not seen, they are felt. Providers 
reiterated how often family and friends of SLE patients believe that the patient is crying wolf or 
exaggerating to receive pity. This misconception about invisible illness is a major downfall in 
creating a supportive environment for patients. Therefore, increasing others’ awareness that even 
though the patient may look okay on the outside their internal body is not okay.  
Specific for General Public. The providers were aware that this measure would be used to 
assess two general public samples’ knowledge of SLE and thus they were asked if they had 
different considerations about how to increase community knowledge. They all agreed that this 
goal is ambitious and hopefully one day we can say that the public is aware and knowledgeable 
but that is far in the future. One provider mentioned that the best hope we have for informing the 
public is to educate the public about invisible diseases overall, not just SLE.  The general 
comment regarding educating the public is to understand that this illness is not a death sentence 
and that it is not contagious, which are two common misconceptions that increase the stigma 
surrounding SLE. 
Phase 2: Reviewing Patient Education and Interview Data 
 Creating the LKQ Items. For the draft version of the LKQ, the items’ content had been 
chosen if such content had been brought up during the interviews with the medical providers 
and/or if the SLE facts were in the LFA’s packets (DeVon, et al., 2007). There is a wide range of 
important SLE facts that were identified by the providers. Therefore, to ensure that the LKQ 
could be used as a general knowledge tool and not contain highly specific and jargon information 
the content was chosen selectively. For example, the providers discussed various details 
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regarding medication regimens that would be important for patients to know, but not necessary 
for the community to know.  
Conducting Directed Content Analysis. The Common Sense Model of Illness (CSM) 
was used to guide the theoretical foundation of the present study. In order to inform the LKQ, the 
dimensions of the CSM (identity, cause, timeline, controllability/curability, consequence) were 
used to generate items. For example, the draft version of the LKQ contained 38 items and of 
those items, 13 were coded as cause. Nine items were coded into the consequence dimension; 
eight items were coded as curability/controllability, seven items were coded for identity, and 
three items were in the timeline dimension. (See Appendix E for LKQ and CSM.)  
Phase 3: Verifying and Revising LKQ Draft.   
The draft version of the LKQ was created, verified by providers and tested for various 
item analyses (e.g., readability and item difficulty). Those results are described below. Edits 
from such revisions were applied to the revised version of the LKQ, which was administered to 
the second community sample.  
Readability. For the draft version of the LKQ, the Flesch-Kincaid grade level or FRES 
score was 8.9, which indicated a ninth grade reading level. The overall scale was grade 
appropriate (Rudd, Moeykens, & Colton, 1999; Terwee et al., 2007). However, one item maxed 
out at 16.5 (lupus increases an individual’s risk of premature cardiovascular disease (heart 
disease)), but others were as low as a second grade reading level (Hair loss in a symptom of 
lupus, 2.3). For the Flesch-Kincaid readability formula (FRF) the score was 49.0 which is 
considered “very difficult” (Friedman & Hoffman-Goetz, 2006). The scores ranged from 10.5 
(bipolar disorder is the most common co-occurring mental health diagnosis) to 95.9 (lupus is 
caused by the same virus that is linked to HIV); see Table 6 for full item difficulty scores. 
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Overall, the grade level score of the draft version satisfied the recommended grade level 
readability.  
 Content Verification. After the survey was drafted, the three medical providers were 
asked to verify the content of the draft version and provide feedback regarding item accuracy and 
clarity. For the draft version of the LKQ, items were created based on the content analysis from 
phase two. All of the results follow; to see which items were retained or excluded based off 
various analysis methods refer to Appendix D. 
 Content Validity Index. The providers were asked to provide relevance ratings on the 
Content Validity Index (CVI) for each item of the LKQ-draft (1= not relevant, 4= highly 
relevant) and provide any additional feedback. A rating of three or four indicated the content was 
perceived as valid and consistent with the conceptual framework of general SLE knowledge, 
whereas, items rated one or two were considered irrelevant and unnecessary, unless, the 
providers gave accuracy feedback (Lynn, 1996).  Items that were deemed irrelevant (CVI score 
of 1 or 2) were deleted unless a provider gave written feedback, the feedback was intended to 
create a relevant item. The items with feedback were edited and retained for the revised version. 
The items that were deemed relevant (CVI score of 3 or 4) were retained. An item score of .80 
(4/5 providers) has been cited for being on the low end of acceptability for item retention (Lynn, 
1986); however, researchers have indicated that a score of .67 (2/3 providers) is acceptable 
(Polit, Beck, & Owen, 2007). Therefore, if at least two of the providers gave a score of 3 or 4, 
that item was retained. There were two expectations. Items number 6 and 21 on the draft version 
were excluded from the revised version due to my subjective opinion of making cuts to the 
length of the questionnaire and because both are relative for the patient and potentially tap into 
perceptions of SLE rather than strict knowledge.  
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 All three providers agreed that two of the items were not relevant (score of 1 or 2). Eleven 
items were unanimously agreed upon as is as being relevant (score of 3 or 4). Provider 1 
provided additional comments for 13 of the 38 items, provider 2 provided comments for 9 of the 
38 items, and provider 3 opted to give no written feedback. Of the 38 items that were included on 
draft LKQ, 28 items were edited for clarity or accuracy (See Appendix D: Verification Feedback 
from Providers). At the end of the verification process, the l I-CVI scores ranged from 1.00 (3/3 
agreement) to 0.00 (0/3 agreement).  
Regression Analysis.  A regression analysis was used to test which of the 38 items of the 
LKQ accounted for the most predictive value for LKQ scores. The 38 items were analyzed 
within a forward regression analysis and the analysis indicated that thirteen items explained 92% 
of the variance (R2=.920, F (1,322) = 5.270, p = .022) of the knowledge scores. Those thirteen 
items significantly predicted the overall score on the LKQ. These data contributed to the decision 
to keep various items because the items’ associations with predicting participants who scored 
better on the LKQ. Additionally, the data from the regression analysis further supported the 
results from the CVI. The regression analysis results can be found in Table 5.  
Item Difficulty. In addition to the items retained based on the CVI and regression 
analysis data, three more items were retained from the draft version to the revised version 
because of my subjective reasoning and the exploratory item difficulty scores they received. Item 
number 36 (bipolar), 38 (Caucasian more than others), and 17 (jaundice) were kept because 
during the exploratory item analysis (discussed below) these three items results in more 
appropriate difficulty scores due to better distributions of true and false responses. Therefore, 
these items were considered key items that were not too easy, but also not too difficult. 
Additionally, all three of these items incorporate concepts that were directly related to what the 
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providers discussed and information mentioned in the pamphlets. Together, these two reasons 
warranted enough support to add them to the revised version to further assess their value as LKQ 
items. To see each item’s difficulty score, see Table 6. 
Phase 4: Testing the LKQ and LKQ-R  
Community Sample 1. The LKQ was administered to the first community sample. The 
results of the first administration of the LKQ are presented below. 
Demographic. There were a total of 345 young adults screened from a community 
sample to be included in the first administration of the LKQ. However, seven participants’ data 
were excluded because they omitted all 38 items on the LKQ. The final sample size included a 
total of 336 participants. The assumption of normality was assessed using the recommended 
Shapiro-Wilk test to determine if the LKQ scores were normally distributed (Ghasemi & 
Zahediasl, 2012). The first sample was reviewed based on the Shapiro-Wilk (SW=.743, df=336, 
p > .001), skewness (1.301), and kurtosis (.562) and the findings suggested that the normality 
assumption was not met. Therefore, nonparametric analyses were used.  
Research Question 2. How do participants in a community sample (the young adult) 
score on the LKQ? 
Lupus Knowledge Questionnaire. The draft version of the LKQ contained 38 items that 
assessed general SLE knowledge. Data from the 336 participants were examined to determine 
the level of knowledge the participants had of SLE. Overall, 160 participants (47.6%) scored a 
zero on the LKQ. The average score on the LKQ was 16.34% (SD= 23.07%) and scores ranged 
from 0% to 92% (Figure 1: LKQ-draft Scores). No participant answered all 38-items correctly. 
Two participants scored the highest with a 92% or 35/38 items answered correctly. Only 45 
participants scored a 50% or higher on the LKQ (13.4%) and 155 (46.1%) participants indicated 
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having no knowledge of SLE by choosing “don’t know” for all 38 items. The majority of the 
participants reported, “don’t know” for all items (Table 7: response rates for each draft item).  
The first sample administration of the LKQ exhibited good internal consistency (Kuder 
Richardson-20 = .960). Items were coded as 0 and 1’s, in that correctly answered items incurred 
a coding of 1, while both incorrectly answered and “don’t know” responses were coded as 0. 
Split-half reliability was also conducted and exhibited an excellent reliability score (Spearman-
Brown =.931) 
Item Difficulty. Item difficulty analyses were calculated for each item. Each score is 
represented by a value, ranging from 0 to 1.00. The closer an item’s score is to 1.00 indicates that 
more participants answered the item correctly while scores closer to 0.00 were answered 
correctly by fewer participants. Item difficulty scores varied for each item based on the number 
of responses accounted for. For the 38 items, item difficulty scores ranged from 0.027 to 0.298. 
As referenced previously, scores ranging between .3 and .8 are ideal (McCowan & McCowan, 
1999). Therefore, scores were unanimously indicative of a very difficult questionnaire. However, 
due to the high degree of “don’t know” responses the low scores were expected. The item 
difficulty scores for each item are presented in Table 6. 
An exploratory item difficulty analysis was also conducted to gain perspective of the 
items without the high rate of “don’t knows.” Scores were calculated by accounting for 
participants who responded with either true or false (i.e. those who felt confident in their 
knowledge and attempted the answer the item) without accounting for the “don’t know” 
responses. For the 38 items, the exploratory item difficulty scores ranged from 0.283 to 0.971. 
The purpose of exploring these scores was to assess the hypothesized item difficulty scores that 
may have been more appropriate with a sample that would have been more knowledgeable.  
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Item Discrimination. Due to the skewed scores of the entire sample (almost half of the 
participants received a score of zero), item discrimination could not be calculated. The item 
discrimination scores would traditionally be calculated when wanting to identify which items can 
discriminate between overall scores of respondents who did well and those who did not. For 
example, to assess each item’s discrimination value, the percent score of the item that was 
attained by the top 27% would be subtracted from the percent score of the percent score attained 
by the lower 27% of the participants who answered that item. Therefore, the equation would look 
similar to this, 16% - 0% = 16%. This sort of discrimination score indicates that the item is 
unacceptable (Sim & Rasiah, 2006).  
Educational Exposure to SLE. Participants were asked to report their current level of 
educational exposure to SLE. When asked whether the participants had heard of SLE, the large 
majority reported yes (N=245, 72.49%). However, when asked about their further exposure to 
the disease, affirmative responses diminished greatly. When participants were asked had they 
read about SLE, learned about SLE in a class, or attended a lecture on SLE the large majority 
reported no for all three, respectively (N=272, 80.47%; N=293, 86.43%; N=331, 97.93%). 
Disease Proximity to SLE. Participants were asked to report any disease proximity to 
SLE by indicating if they had a personal diagnosis, a family member (immediate or extended) 
diagnosed and/or if they knew any other person living with SLE. If they reported “yes” they 
were asked to identify the relationship of that individual (e.g., friend, neighbor, mother-in-law). 
Participants were given the option to not respond to these items without repercussions. Of the 
328 who replied when asked about a personal diagnosis, only three participants reported 
personally having a diagnosis of SLE (0.09%) and twenty-two reported knowing a family 
member (immediate=8; 2.4%, extended=14; 4.6%) who has a diagnosis. An additional 34 
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participants reported knowing some other person with an SLE diagnosis (10.4%; Table 2: 
Disease Proximity Frequency).  
Perceptions of Knowledge. Participants were asked to report on how confident they were 
of their current accuracy of SLE knowledge prior to taking the LKQ. Only seven participants 
reported feeling “confident” in their knowledge and an additional five felt “extremely confident,” 
totaling only 3.6% of the sample. The remaining 323 participants reported either no confidence, 
some confidence or that they were unsure (N=238, 70.8%; N=49, 14.6%; N=36, 10.7%, 
respectively).  
Participants were also asked to report how they perceived their own knowledge of SLE 
compared to the average person. Only a total of 8% of the sample believed they had more 
knowledge of SLE than the average person (Much More Knowledge = 5; More Knowledge= 22). 
Ninety-one participants reported having less knowledge than the average person (27.1%). The 
highest group reported that they had much less knowledge about SLE than the average person 
(N=114, 33.9%). The rest reported believing they had the same level of knowledge as the average 
person (N=101, 30.1%). Overall, people believed they had less knowledge of SLE than the 
average person. 
Hypothesis 1. Individuals with educational exposure to SLE will have higher scores on 
the LKQ than those who have no exposure to SLE. 
A Kruskal-Wallis one-way ANOVA was conducted to assess rank differences between 
the educational exposure groups. Group 1 consisted of participants who had heard of SLE 
(N=160), group 2 consisted of those who had endorsed at least one of the other exposure items 
(read about SLE, attended lecture, and/or read about it; N=86), and group 3 consisted of those 
who had reported having none of the above educational exposures (N = 89). Results indicated 
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that there was a statistically significant difference in LKQ scores earned by those with different 
educational exposure, χ2(2) = 96.12, p < .001, with a mean rank of 169.85 for group 1, 235.25 for 
group 2, and 99.69 for group 3.  
A post hoc sums test indicated that participants who reported having heard of SLE (group 
1; 105.45) scored significantly lower on the LKQ than those who had had a deeper educational 
experience (group 2; 157.16), χ2(1) = 30.83, p < .001. Secondly, participants who reported 
having learned about it in a deeper educational experience (group 2; 122.51) scored significantly 
higher on the LKQ than those who reported no educational exposure (group 3; 56.01), χ2(1) = 
30.83, p < .001. Similarly, individuals who had heard of SLE (group 1; 145.73) scored 
significantly higher on the LKQ than those who reported no educational exposure (group 3; 
89.54), χ2 (1) = 43.22, p < .001.  
Hypothesis 2. Individuals who have closer proximity to SLE will have higher scores on 
the LKQ than those who indicate having no proximity to SLE. 
A Kruskal-Wallis one-way ANOVA analysis was conducted to assess rank differences 
between the disease proximity groups. Group 1 consisted of those who self-identified as having 
SLE and/or indicated an immediate or extended family member had SLE (N=22). Group 2 
consisted of those who indicated that they knew someone else with SLE (N=29). Group 3 
consisted of people who reported that they knew no one with SLE (N=276). Results indicated 
that there was a statistically significant difference in LKQ scores earned by those with different 
disease proximity, χ2 (2) = 36.23, p < .000, with a mean rank of 245.84 for group 1, 222.40 for 
group 2, and 151.34 for group 3.  
A post hoc rank sums test indicated that participants who reported having close proximity 
(group 1; 27.84) did not statistically differ from those who reported knowing someone else with 
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SLE (group 2; 24.60), χ2 (1) = 0.60, p = .440. However, those with close proximity to SLE 
(group 1; 229.50) compared to those with no proximity (group 3; 143.12) scored significantly 
higher on the LKQ, χ2 (1) = 23.28, p < .001. Similarly, those with other proximity (group 2; 
212.79) compared to those with no proximity (group 3; 146.72) also scored significantly better 
on the LKQ, χ2 (1) = 16.78, p < .001.  
Community Sample 2: 
Demographic. The final sample size for the administration of the LKQ-R was 188 
participants because those participants correctly answered the validity item. The assumption of 
normality was assessed using the recommended Shapiro-Wilk test (Ghasemi & Zahediasl, 2012). 
The second sample was reviewed based on the Shapiro-Wilk (SW=.743, df=336, p > .001), 
skewness (1.301), and kurtosis (.562) the findings suggested that the assumption of normality 
was not met. Therefore, nonparametric analyses were used.  
Research Question 2. How do participants in a second adult community sample score on 
the LKQ-R? 
Lupus Knowledge Questionnaire-Revised. The revised version of the LKQ used in the 
second sample contained 34 items. Of the 188 participants, no one received a score of zero. 
Seventeen participants received a score of 3% by getting 1/34 items correctly (9.0%). The 
average score on the revised version was 41.16% (SD= 22.80%) and scores ranged from 3% to 
94%. Overall, no participant answered all 34 items correctly. Only one participant scored the 
highest with a 94% or 32/34 items answered correctly. Seventy-five participants scored a 50% or 
higher on the LKQ-R (39.89%). Figure 2 provides a pie chart of the LKQ average range scores 
for the second sample (see Table 13: LKQ-R Response Rates). For the revised version of the 
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LKQ, items were retained based on CVI scores, a regression analysis, and information gathered 
through the item difficulty analysis. 
The LKQ-R exhibited good internal consistency (Kuder Richardson-20 = .940). Items 
were coded as 0 and 1’s, in that correctly answered items incurred a coding of 1, while both 
incorrectly answered and “don’t know” responses were coded as zero. Split-half reliability was 
also run and exhibited good reliability (Spearman-Brown Coefficient= .889). 
Participants were asked whether they had educational exposure and disease proximity. 
Therefore, in order to assess if those who reported educational exposure also more commonly 
reported disease proximity a chi-square analysis was conducted. The analysis indicated that there 
was a statistically significant association between those who identified as having proximity to 
SLE and those who identified having educational exposure to SLE, X(6)=14.988, p =.0.020. The 
Phi value (.284, p=0.020) indicates a medium strength association.  
Readability. For the final version, the overall Flesch-Kincaid grade level or FRES score 
was 8.7, indicating a near ninth grade reading level, which is appropriate (Rudd, Moeykens, & 
Colton, 1999; Terwee et al., 2007). The score range for individual items decreased after edits 
occurred for the revised version to be between a score of 3.6 (treatment can cure lupus) 13.9 
(bipolar disorder is the most common co-occurring mental health diagnosis for lupus patients). 
For the Flesch-Kincaid readability formula (FRF), scores range from 0 (very difficult) to 100 
(very easy). The score scale’s score was 49.6, which is considered difficult (Friedman & 
Hoffman-Goetz, 2006). The scores ranged from 17.9 (bipolar disorder is the most common co-
occurring mental health diagnosis for lupus patients) to 82.3 (hair loss/thinning is a symptom of 
lupus); see Table 12 for item’s score. Overall, changes on the FRES and FRF slightly improved.  
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Certain items that contained more jargon language (e.g., cardiovascular disease, bipolar, 
co-occurring) incurred higher ratings of difficulty, which increased the score. Items were not 
deleted based on their FRES or FRF score because some items were in the appropriate range for 
one or the other score (e.g. either reading ease or grade level). Additionally, previous researchers 
have had items that exceed the aimed score, but because their overall score remained appropriate 
the items were retained but incorporated further explanations (e.g., heart disease and explaining 
genetic predisposition; Rhee et al., 2013).  
Item Difficulty. Item difficulty was calculated for each item. Each score is represented by 
a value ranging from 0 to 1.00. The closer the score was to 1.00 the more participants answered 
the item correctly and items with a score closer to 0.00 were answered correctly by fewer 
participants. Item difficulty scores ranged from 0.048 (item 23, immune count test) to 0.711 
(item 25, immune system weakened). Even though item 20 revised a score of 1.00, it was not 
included in the difficulty range, because this item was used as the validity item and everyone 
included answered that item correctly. The item difficulty scores for each item of the revised 
version are presented in Table 12.  
Item Discrimination. For the second sample, scores were more variable without the 
influx of don’t knows and zeros and therefore, item discrimination was calculated. The higher 
the discrimination index the better the item can determine the difference between participants 
who score high and those who score low on the questionnaire (Sim & Rasiah, 2006). Scores of 
.40 and higher are considered desirable (McCowan & McCowan, 1999). Items on the revised 
version were calculated for item discrimination by computing the differences between the top 51 
participants and the bottom scoring 51 participants (top and bottom 27%). Discrimination scores 
ranged from 11.7% to 85.1%. Only three of the 34 items received an “unacceptable” score (item 
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23,30,32); however, these items provided insight for what presumptions are believed by many 
community members. For this reason, they should be retained for further examinations of the 
efficacy of the LKQ-R (see Table 12). 
Educational Exposure to SLE. Participants were asked to report their current level of 
educational exposure to SLE. When asked whether participants had heard of SLE, the large 
majority reported yes (N=179, 95.2%). Almost half the sample reported having read about SLE 
(N=84, 44.7%). However, only six participants reported having attended a lecture on SLE 
(3.2%). Finally, 24 participants reported having learned about SLE in a class (12.8%; see Table 
11: Educational Exposure Frequency). 
Proximity to SLE. Participants were asked to report on their proximity to SLE. The 
participants were asked to report on a personal diagnosis, a family member diagnosis and/or any 
other person they know diagnosed with SLE. If they identified a person, they were asked to 
describe the relationship of the individual. Participants were given the option to not respond to 
the following items without being penalized. Of the 188 participants who were included in the 
final analyses, 186 participants opted to reply to the disease proximity items. When asked about 
a personal diagnosis, three participants reported having a diagnosis of SLE (1.6%) and twenty-
two reported having a family member (immediate= 4, 2.1%, extended=18, 9.6%) diagnosed. An 
additional 48 participants reported knowing some other person with SLE (25.5%; see Table 9: 
Disease Proximity Frequency).  
Perception of Knowledge. Prior to taking the LKQ-R, participants were asked how 
confident they were of their SLE knowledge. Only ten participants (5.3%) reported feeling 
confident in their knowledge and just one participant reported feeling extremely confident, 
together accounting for 5.8% of the sample. Half of the sample reported having no confidence in 
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their knowledge (N=94, 50.0%). While another 25% of the sample reported having some 
confidence (N=47). The remaining participants reported being unsure about their knowledge of 
SLE (N=36, 19.1%). 
Following the LKQ-R, participants were asked to report on how they believe their level 
of knowledge compared to the average person. Almost half of the sample reported having the 
same knowledge that the average person has (N=92, 48.9%). A total of 59 participants reported 
having less knowledge (N=33, 17.6%) or much less knowledge (N=26, 13.8%) than the average 
person. However, 37 participants reported feeling as though they had more knowledge (N=31, 
16.5%) or much more knowledge (N=6, 3.2%) than the average person. 
Hypothesis 1. Individuals with educational exposure to SLE will have higher scores on 
the LKQ than those who have no exposure to SLE. 
A Kruskal-Wallis one-way ANOVA was conducted to assess the relationship between 
LKQ-R scores and participants’ educational exposure. Group one consisted of those who had 
heard of SLE (N=93), group 2 consisted of those who had endorsed at least one of the other 
exposure items (read about SLE, attended lecture, and/or read about it; N=85), and group 3 
consisted of those who had reported having none of the above educational exposures (N = 9). 
Results indicated that there was a statistically significant difference in LKQ scores earned by 
those with different educational exposures χ2(2) = 47.09, p < .001, with a mean rank of 68.51 for 
group 1, 123.66 for group 2, and 77.33 for group 3.  
A post hoc sums test indicated that participants who reported having a deeper educational 
experience with SLE (group 2; 116.75) scored significantly higher on the LKQ than those who 
had only heard of SLE (group 1; 64.59), χ2 (1) = 45.59, p < .001. Additionally, participants who 
reported having learned about SLE in a deeper educational experience (group 2; 49.91) scored 
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significantly higher on the LKQ than those who reported no educational exposure (group 3; 
24.78), χ2 (1) = 6.92, p =.009. However, the LKQ scores for individuals who had heard of SLE 
(group 1; 50.91) did not differ significantly compared to those who reported no educational 
exposure (group 3; 57.56), χ2 (1) = 0.42, p =.519.  
Hypothesis 2. Individuals who have closer proximity to SLE will score higher on the 
LKQ than those who indicate having no proximity to SLE. 
A Kruskal-Wallis one-way ANOVA was completed to assess the relationship between 
LKQ-R scores and disease proximity. Group 1 consisted of those who endorsed having a 
personal SLE diagnosis and/or those who indicated having a family member (immediate or 
extended) with SLE (N=21). Group 2 consisted of those who indicated that they knew someone 
else with SLE (N=43). Group 3 consisted of people who reported that they knew no one with 
SLE (N=122). Results indicated that there was a statistically significant difference in LKQ scores 
earned by those in different disease proximity groups, χ2 (2) = 16.044, p < .001, with a mean rank 
of 124.40 for group 1, 109.80 for group 2, and 82.43 for group 3.  
A post hoc rank sums test indicated that participants who reported having a close 
proximity (group 1; 36.31) did not statistically differ between those who reported knowing 
someone else with SLE (group 2; 30.64), χ2 (1) = 1.312, p = .252. However, both group 1 and 
group 2 scored significantly higher on the LKQ than those who indicated knowing no one with 
SLE. Those in the close proximity group (group 1; 99.10) compared to those who reported no 
proximity to SLE (group 3; 67.34) scored significantly higher on the LKQ, χ2 (1) = 10.55, p = 
001. Similarly, those who reported knowing someone else with SLE (group 2; 101.16) compared 
to participants who reported knowing no one with SLE (group 3; 76.60) scored significantly 
higher on the LKQ, χ2 (1) = 8.421, p =.004.  
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Discussion 
 The purpose of this study was to 1) create a novel SLE disease-specific knowledge 
questionnaire and 2) assess the knowledge of community members using the LKQ. The specific 
hypotheses were created to assess whether having learned about SLE in an educational setting 
(i.e., educational exposure) as well as the effects of knowing about SLE on a more personal level 
(i.e., disease proximity) were related to scores on the knowledge questionnaire. A four-phase 
design was used to execute the study; the initial three phases involved the foundational work of 
creating the SLE knowledge questionnaire and the final phase consisted of administering the 
LKQ to two unique samples. Hypothesis one was supported: those with deeper educational 
exposure to SLE earned a higher score on the LKQ than those with no exposure. Hypothesis two 
was also supported: those with closer disease proximity to SLE earned a higher score on the 
LKQ than those with no proximity. Further findings also emerged and are reviewed below.  
Results of Research Question 1 
 In order to create a medically accurate knowledge questionnaire interviews with medical 
provider were used. The interviews were the foundation of research question 1, which was to 
determine what topics related to SLE medical providers believed were important to be included 
in the novel Lupus Knowledge Questionnaire. 
Understanding the experience of a chronic illness involves understanding that illness is a 
complex process where disease-specific information is constantly being added, subtracted and 
adapted throughout the life (Hale, Treharne, & Kitas, 2007). Just as the providers reflected, 
understanding the experience of SLE is not unidimensional. Thus, the Common Sense Model of 
Illness was chosen as the theoretical framework to support the interviews because of its 
supported of the comprehensive evaluation of the dimensions of life with a chronic illness 
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(Cause, Identity, Timeline, Controllability/Curability, Consequence; Diefenbach & Leventhal, 
1996; Hagger & Orbell, 2003).  
Responses related to the cause of SLE involved mention of the involvement of genetics, 
environmental hazards, and hormones all of which have been linked to the onset of SLE (Sestak 
et al., 2007; Marengo et al., 2012; Crampton, Morawski, & Bolland, 2014). Although not all 
trigger factors have been identified, many known risk factors include exposure to sunlight, direct 
exposure to various hazardous chemicals, pregnancy, and increased life stress.  
Discussions of the identity (i.e., symptoms) of SLE involved mention that each case looks 
differently, so although many symptoms are common the variability of experience between each 
SLE case varies between mild and severe, which has been substantiated in previous work 
assessing SLE (Sutanto et al., 2013) A number of symptoms linked to SLE that the providers 
mentioned, including invisible and visible. The course or timeline of SLE resulted in some 
variability in answers from the providers because the disease can be difficult to identify and 
diagnose. The repercussions of the lengthy diagnostic process and how important it is that 
treatments are started early is important for having a more controlled disease (Giffords, 2003).  
Understanding SLE involves recognizing that the disease is controllable, but not curable. 
SLE is a chronic condition; however, due to medical advances, it is much more manageable. 
Two common misconceptions that the providers discussed were that SLE is a death sentence and 
that it can be caught (e.g., sexually or through saliva). Previous research has indicated that some 
reasons that patients do not adhere are because they have a decreased perception of the necessity 
of medication use, belief that other non-medical treatments are better, and do not have a clear 
understanding of the importance of the medication for SLE treatment (Carder, Vuckovic, & 
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Green, 2003; Chambers et al., 2009; Harrold & Andrade, 2009; Williams, Manias, & Walker, 
2008). Understanding how SLE occurs is again important for understanding how to control it.  
The consequence informed the understanding of how patients work to understand and 
adapt their life to understand how to now live with their disease. SLE has the potential to 
influence physical well-being as well as social and mental well-being (Kool et al., 2010; Kool & 
Geenen, 2012). Patients also are at increased risk of comorbid diagnoses, both mental (e.g., 
depression, anxiety; Nery et al.,2008; Bachen et al.,2009) and physical (e.g. fibromyalgia; Lam 
& Petri, 2005). Therefore, patients must involve a high level of symptoms monitoring, which 
becomes one of the main objectives after a diagnosis is received (Lam & Petri, 2005). 
Management of daily activities and specific health behaviors were mentioned by the providers as 
being important. These behaviors included maintaining a moderately active lifestyle (e.g., 
nonaerobic), incorporating a healthy diet, avoiding prolonged sun exposure, quitting smoking, 
and practicing correct medication management. Practicing these modifications minimize the 
severity of SLE symptoms as well as minimize the likelihood of further disease consequences 
(e.g., neurological concerns, heart disease (Parrondo, 2011; Lam & Petri, 2005).  
The majority of the interview time was spent discussing topics related to the needs of 
patients; a portion of time was spent discussing what family, friends, social supporters, and the 
general public should know about SLE. Many of the topics mentioned previously were reiterated 
as being important for these other individuals. Especially supporters, people who interact with 
patients daily or who accompany patients to office visits should be knowledgeable of SLE. The 
knowledgeable support of a family member or spouse has been found to ease the worries that 
patients have when visiting doctors (Karlson et al., 2004). Just as there were two common 
misconceptions mentioned that newly diagnosed patients often report, two misconceptions that 
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need to be eliminated for supporters and the public’s repertoire are: “it’s all in your head” and 
“…but you look fine.” These misconceptions diminish the experience of SLE for the patient’s 
daily life and perpetuate the negative stigma that is associated with invisible illness. 
Results of Research Question 2 
Phase 4 consisted of determining how participants scored on the LKQ, which provided 
initial psychometric data for the LKQ. Two samples worth of data were collected, with one 
sample being administered the draft version of the LKQ and the second sample was administered 
a revised version.  
The results gathered from sample one became influential learning steps that informed the 
creation of the revised version used in sample two. The information learned through the item 
analyses indicated that the scale had good reliability, which is essential for laying the foundation 
for a new measure to be trusted. However, item difficulty scores were low and indicative of 
extremely difficult items. Even more, item discrimination was not conducted because of the 
inappropriate representation of knowledge from the sample. Item analyses, although resulted 
with values the trustworthiness of the values is called into question. Overall, the findings from 
sample one’s examination of the LKQ and the results of the content validity index feedback, the 
regression analysis, and the item analyses informed the revised version.  
Participants in sample one scored quite poorly on the LKQ with only averaging about a 
16%, largely contributable to the 46% of participants who choose all “don’t knows.” The large 
number of participants who scored zero skewed the overall samples interpretation values. 
Therefore, after recognizing this influx in don’t know response a validity item was used in 
sample two. Overall, sample one’s scores were likely influenced by three concerns; 1) the sample 
consisted of young adults which often times results in lack of attention to the questionnaire; 2) 
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the large majority of don’t know responses skewed the overall scores; 3) there was no validity 
item in sample one. Therefore, the results gathered in sample one are not as reliable as sample 
two’s results. Although the results of sample one were not as trustworthy, the findings were 
informative of how to make improvements for sample two.  
Identifying the challenges and results from sample one helped inform revisions that 
improved the LKQ-R. A weakness in the design from sample one was that there was no way to 
exclude for participants who did not provide full effort in responding to the knowledge 
questionnaire. Therefore, the addition of the validity item improved the trustworthiness of the 
data from the second sample. This can be evident because the item difficulty scores were almost 
all exclusively in the appropriate range as were the item discrimination scores. The 
improvements to the LKQ-R resulted in more appropriate analyses. Together, these findings 
suggest that the revisions made to the LKQ to create the LKQ-R improved the overall clarity of 
the results. An alternative explanation is that the participants had increased familiarly with SLE 
and were able to exhibit a better range of knowledge. Further assessment of the questionnaire 
should continue.  
Overall, the inclusion of a validity item on the LKQ-R was likely the most influential edit 
that occurred. One criticism of having a True, False, and Don’t Know response format is that 
participants can receive an “out” by choosing all don’t know and thus, they choose only don’t 
knows (Beatty & Herrmann, 1995). The validity item allowed for me to be able to identify those 
individuals who did not provide their full attention to the questionnaire and used the don’t know 
option as an “out.”  The scores on the revised LKQ increased, with an average score of about 
41%. The results indicated that a positive shift towards better scores occurred over the two 
studies.  
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To supplement the focus of the current study and explore participants’ performance on 
the LKQ and LKQ-R they were asked to rate their pre- and post- test perceptions of their SLE 
knowledge. The majority of both samples’ participants reported having no confidence in their 
knowledge of SLE (70%, sample 1; 50%, sample 2). Participants from both community samples 
were quite open about having limited knowledge of SLE. Overall, the majority of participants 
rated closer to the not confident end of the scale than towards the confident end. Additionally, 
after completing the questionnaires, participants were asked to compare their knowledge of SLE 
to the average person. Almost 50% of the second sample reported having the same level of 
knowledge as an average person. Overall, the second sample showed an increase in having more 
knowledge and much more knowledge than the average person and fewer people reported having 
less knowledge and much less knowledge than the average person. This may reflect the 
trustworthiness of sample two over sample one. The age difference between the samples (i.e., an 
average age of 21.5 in sample 1 compared with an average age of 33 in sample 2) might 
represent differences in maturity and life experience. These factors, in turn, could have 
accounted for some of the differences in knowledge. Of course, these hypotheses were not 
evaluated within the context of this particular study.  
Based on the results from the current study the average level of SLE knowledge is quite 
low. However, since no study has examined SLE knowledge among community members there 
was previously no known rate of SLE knowledge. Therefore, understanding the perceived level 
of knowledge and identifying the average LKQ and LKQ-R scores allows for the opportunity to 
explore and develop advocacy efforts aimed at increasing accurate knowledge. The average 
persons’ knowledge, based on findings from this study and the questionnaires, indicates that 
knowledge is likely somewhere between 16% and 41%. Even more, participants believed they 
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had much lower knowledge compared to the average person. Together these indicate that 
community members are confidently unaware of SLE. This low level of SLE knowledge and 
perceptions of knowledge among the community is why this area of research is important. Being 
misinformed about SLE has negative repercussions for the SLE community, such that, being 
unaware of SLE could likely result in increased stigmatization of patients.  
Results of Hypothesis 1 
 Hypothesis 1 was supported; individuals who reported having educational exposure to 
SLE scored significantly higher on the LKQ than those who reported no exposure.  
Rates of Educational Exposure. For the first community sample, 72% had heard of SLE. 
However, any deeper level of educational exposure was quite rare with 80% of the sample 
reporting having never read about SLE. For the second community sample, even more of the 
sample (95%) had heard of SLE. All other levels of educational exposure were again, quite low. 
These results indicated that having heard of SLE was quite common; however, reports of having 
opportunities to learn more about SLE through deeper educational means decreased drastically. 
Sample One. During the examination of hypothesis one, the three comparison analyses 
conducted indicated that there were significant differences among the educational exposure 
groups. Participants who reported having only heard of SLE were compared to those who 
reported having a deeper educational experience with SLE. The presumption was that having a 
deeper learning experience of SLE would mean that a person was able to understand SLE at a 
deeper level compared to those who had only heard of SLE. The findings of this analysis 
indicated that having heard of SLE held no significance when it comes to being knowledgeable 
about the disease mechanism of SLE.  
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The deeper educational exposure group was compared to those who reported no 
educational exposure to SLE. Although this may seem like a simple assumption because no 
study had examined SLE knowledge among community members with a questionnaire there had 
never been a way to examine the relationship between educational exposure and knowledge. 
Therefore, although these findings may be viewed as common sense, the examination and 
findings related to the relationship between educational exposure and LKQ scores were novel. 
Lastly, those who reported having heard of SLE scored significantly higher on the LKQ than 
those who reported having no educational exposure to SLE. The result indicates that for this 
sample having heard of SLE did relate to having higher scores of knowledge when compared to 
those who reported no educational exposure. However, due to sample one’s skewed scores, the 
result that hearing of SLE is associated with higher knowledge scores should be interpreted with 
caution. Rather, the findings and conclusions drawn from sample two appear to provide more 
trustworthy results. 
Sample Two. During the examination of hypothesis one for the LKQ-R, the analyses 
indicated that there was a significant difference among the groups. Further, three comparison 
examinations were employed to determine what groups scored significantly different than the 
others. Individuals who reported having a deeper educational exposure to SLE scored 
significantly higher on the LKQ than those who reported having only heard of SLE. This support 
of the hypothesis indicates that just having heard of SLE holds no weight when it comes to being 
knowledgeable about the disease mechanisms of SLE compared to having the opportunity to 
learn about SLE in a learning environment. Additionally, those who reported having learned 
about SLE in a deeper educational experience scored significantly higher on the LKQ than those 
who reported no educational exposure.  
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Although the finding may seem like common sense the novel analysis and examination of 
these variables further substantiates the relationship between having educational exposure to 
SLE and performing better on an SLE knowledge questionnaire. Finally, LKQ scores for 
individuals who had heard of SLE did not differ significantly from those who reported no 
educational exposure of SLE. These results indicate is that there seems to be no measurable 
difference between SLE knowledge of someone who had only heard of SLE versus having no 
exposure to SLE. These results are different than those from sample one.  
The difference between results could be explained by the inability to exclude data from 
sample one analyses because of not having the validity item. This hypothesis is why the validity 
item was included in sample two and I propose that the questionnaire design better substantiates 
sample two’s results. Additionally, the differences between the demographics of sample one and 
sample two likely informed the motivation and effort of the participants’ performance on the 
measures; thus, it is my second hypothesis regarding why the relationship between hearing of 
SLE and having no educational exposure differed between the two samples.  
The implications of having no measurable difference in SLE knowledge scores when 
having only heard of the illness versus having no educational exposure to SLE is cause for some 
alarm. The concern lies in the presumption that people who have heard of SLE are likely 
unknowledgeable (according to these results) about the factual experiences of SLE but because 
they have some awareness of the illness (i.e., the name) they could be contributing to the societal 
misconceptions of SLE. If they are reinforcing false notions about SLE these individuals could 
be perpetuating inaccurate facts as true. Increasing accurate knowledge has the possibility to 
decrease the negative stigma and misconceptions of SLE that are associated with invisible 
illnesses, like SLE. 
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Results of Hypothesis 2 
Hypothesis 2 was supported; individuals who report having close proximity to SLE 
scored significantly higher on the LKQ than those who do not have disease proximity.  
Rates of Disease Proximity. Participants who reported having SLE, often times also 
reported having a family member with SLE. These results are indicative of the genetic nature of 
SLE (Ramos & Brown, 2010; Sestak et al., 2007; Harley et al., 2006). Some participants even 
reported knowing someone of every relation (self, immediate, extended and other), which due to 
genetics and the likelihood of meeting other people with SLE through support groups these 
results are not surprising.  
Sample One. During the examination of hypothesis two of the draft version, results 
indicated that there was a significant difference among the disease proximity groups. Additional 
tests were employed to determine where the significant differences existed. Individuals in the 
close proximity group were compared to those in the other proximity group and the scores 
indicated no significant difference. The participants who reported having close proximity (self or 
family) did not score differently than those who reported knowing someone else with SLE. 
Initially, there is was a presumption that having someone of close relation (e.g., self, immediate 
and extended family) would have more influence on the participant’s knowledge of SLE than 
knowing someone of other relations. However, the findings indicated that it did not matter what 
relation the person had to someone with SLE; rather, just knowing someone with SLE influenced 
participants’ SLE knowledge. Someone reporting having an aunt with SLE may mean the same, 
in terms of the influence of knowledge, for the participant as having a friend with SLE.  
Those with close proximity to SLE scored significantly higher on the LKQ compared to 
those with no proximity. Similarly, those who reported knowing someone else with SLE scored 
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significantly better on the LKQ than those with no proximity. Therefore, these two results 
indicated that having some personal relation to a person with SLE results in having significantly 
better scores on the LKQ. As highlighted during the discussion of hypothesis one, although these 
findings may seem like a simple assumption because no study has examined SLE knowledge and 
the effects of disease proximity, this conclusion could not be confirmed. One possible 
explanation for this could be that knowing someone with SLE provides the participant an 
opportunity to learn about SLE through the personal experiences of someone diagnosed and/or 
encourages the participant to educate him or herself on the disease. Of note, there was a 
statistically significant association between those who identified as having proximity to SLE and 
those who identified having educational exposure to SLE.   
 Sample Two. During the examination of hypothesis two for the revised version, the 
overall analysis indicated that there was a significant difference among the proximity groups. 
Post hoc tests were employed to determine where the significant differences existed. Although 
the results from sample one should be taken with caution, the results of hypothesis two for the 
second sample were identical. Participants who reported having a close proximity did not 
statistically differ between those who reported knowing someone else with SLE. There seems to 
be no indication that having a closer relationship (as categorized for this study) holds any 
significance to resulting in higher knowledge. Those in the close proximity group and those in 
the other proximity group scored significantly better on the LKQ than those who reported 
knowing no one with SLE. Both results indicate that having some relation to a person with SLE 
results in higher scores on the LKQ. It seems that when someone knows a person with SLE they 
are more inclined or more likely to be exposed to facts or life experiences of SLE and therefore, 
are more knowledge. 
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One possible conclusion that could explain both samples’ findings, in terms of disease 
proximity, is that having any relation to someone with SLE results in one being better educated 
about the disease. It does not seem to differ between the relation that the person holds (close vs. 
other) but having any proximity to SLE is associated with higher knowledge of SLE compared to 
someone who knows no one with SLE. Ultimately, there are too many illnesses in our society to 
be knowledgeable about all of them. Thus, knowing anyone with SLE might serve as an 
incentive or an opportunity to discuss the disease. There is something important about knowing a 
person with SLE that makes others more knowledgeable of the disease. 
Study Limitations 
Although the current studies’ hypotheses were supported, the samples utilized were not 
the typical beginning point of questionnaire development, because they consisted of community 
members and did not all have a direct relation to SLE. Sample one of the current study consisted 
of young adults ranging from age 18 to 24 and sample two consisted of parents who ranged from 
20 to 54 years old. A major consideration that has been mentioned is that the samples were not 
ideal and furthermore, the findings from sample one should be taken with caution due to the 
design flaw with no validity item. The ideal sample that previous researchers have utilized when 
creating a novel or adapting a disease-specific questionnaire is one that incorporates 
“knowledgeable participants”, this includes: patients, providers and those who work in a setting 
where they need knowledge of the condition (Jaworski & Carey, 2007; Carey & Schroder, 2002; 
Bergman et al., 2011; Wagner et al., 2005; White et al., 2006; Giordano et al., 2010; Winzenberg 
et al., 2003; Edworthy, Devins, & Watson, 1995).  
Provided that the samples utilized were not ideal, modifications had to occur when it 
came to assigning participants to the groups. The participants were asked to report any 
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educational exposure (heard of, read about, learned in class, attended lecture) and disease 
proximity (self, immediate, extended family, other) regarding SLE. After responses were 
tabulated, participants were categorized into only one group for each variable. Still, some 
participants reported more than one degree of educational exposure or disease proximity. 
Nevertheless, they were categorized into groups depending on which group they identified with 
that had the lowest number of participants who also endorsed that item. For example, if someone 
reported having attended a lecture on SLE and reported hearing about SLE, that person’s data 
were put into the deeper educational group rather than the heard of SLE group. The same 
occurred for disease proximity, if a participant endorsed having a self-diagnosis of SLE and 
knowing someone else with SLE, their data was put into the close proximity group. Overall, this 
grouping system was not ideal; however, since the results supported the hypotheses it may not be 
as significant of a limitation.  
 A final limitation of the current study exists because the current study’s hypotheses; 
however, altering the research aims could correct for the limitation. Individuals in both samples 
were asked whether they had heard of SLE and in both samples some individuals reported not 
having ever heard of it. For the purpose of the current hypotheses, these participants were 
valuable. That was the case because I wanted to understand the relationship between all 
dimensions of educational exposure and disease proximity, including those who identified as 
having none. However, those participants’ data were still included in the item analyses of the 
LKQ and the LKQ-R. The limitation lies in the issue that by keeping those individuals’ data in 
the final analyses the interpretation of the knowledge questionnaire as a whole includes data 
from individuals who had never even heard of SLE, which is not informative to understanding 
what items are indicative of higher knowledge.  
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Future Directions  
Future research designs should be aimed to correct the limitations mentioned for the 
current study. Further assessments of the LKQ-R should involve increasing the number of 
participants within each educational exposure and disease proximity group. Although the 
grouping procedure used provided appropriate participants, the number of participants in the 
“none” groups (both for disease proximity and educational exposure) were substantially lower 
than the number of participants in the other two groups in the two variables. Since some 
participants endorsed more than one item (e.g., I have heard of SLE and I have read about it in a 
class) there is a chance that a deeper understanding of SLE knowledge was lost because 
participants’ data were not assessed based on more than one endorsement of each variable. 
Future designs should employ independent groups to ensure that the results can be replicated.  
For the current study, assumptions were made regarding which grouping category held 
more weight; however, it is hard to presume the influence of various educational experiences or 
the strength of the relationships participants reported on. Therefore, for future examinations 
adding items to assess the perceived strength of the participants’ educational exposure to SLE 
(i.e., to what degree did you learn about SLE in a class) as well as have a way to assess the 
strength of the relationship between the participant and the person/people they identify as 
knowing with SLE (i.e., does an immediate family member represent a stronger relationship vs. 
extended family vs. knowing someone else) could provide more valuable information. A 
participant only hearing of SLE on a television show versus having heard of SLE from a patient 
could indicate a stronger relationship and expand the current understanding of the dimensions 
that lead to higher knowledge rates (i.e., what is associated with more knowledge). Additionally, 
a specifier aimed at determining the strength of the relationship that a person indicated when 
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endorsing the disease proximity items could be informative. For example, a familial relationship 
may not be conducive of more SLE knowledge; rather, having a close friend diagnosed may be a 
stronger relationship that is conducive to a participant having more SLE knowledge.  
This study was the first step in a broader research agenda designed to continue to 
understand the influence of SLE knowledge. As the first step, the aim was to create a 
questionnaire and conduct preliminary analyses to explore community members’ knowledge. 
The next step should be to assess the utility of this measure in patient and provider samples. 
Those are the samples that are theoretically presumed to have more knowledge of the disease and 
thus, these samples would be the typical starting point (Reeve et al., 2013). Utilizing patients and 
gathering psychometric data on the measure within this sample will allow for the future use of 
the LKQ-R as an additional measure within protocols of patient education research. With further 
use and examinations of the LKQ-R, it is the hope that it will become a common measure that 
future researchers can use to assess the influence of SLE knowledge in various research designs. 
Similarly, utilizing a provider sample will allow for the LKQ-R to be aimed at examining the 
rates of knowledge that providers have of SLE and where gaps exist. New interventions can be 
aimed to increase medical providers’ knowledge.  
A final consideration is that the scope of the current study did not fully address all results 
gathered. In fact, more data was gathered that could be examined to address alternate hypotheses, 
including ones regarding what content areas of knowledge are scored at higher rates or which 
various items on the LKQ-R are scores correctly more often than others. Understanding details 
regarding which items are scored correctly more often could inform our considerations of what 
knowledge themes are more well-known, which would be more novel insights. For instance, 
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understanding what categories of disease proximity and educational exposure could have related 
to a higher correct rate of individual items or the overall scale score.  
Contribution to the Literature 
 Although some limitations exist, the findings from this study have provided a novel and 
monumental method of exploring the dimension of SLE knowledge. As mentioned previously, 
no measure like the LKQ-R exists; therefore, the creation of the LKQ-R is a novel contribution 
to the field. The results from the assessment of the LKQ and the LKQ-R within the two 
community samples provide the first examination of disease-specific knowledge and the effects 
of education and proximity. The findings support the notion that educational experience and 
disease proximity contribute to SLE knowledge, which are novel scientific contributions. 
Clinical Implications  
 After continued testing within patient and provider samples, it is my hope that the LKQ-
R will become a commonly utilized measurement tool to assess SLE knowledge in a systematic 
way. The questionnaire could be used by providers to educate newly diagnosed patients. Patients 
report being unsatisfied with the information that their providers give them after receiving a 
diagnosis (Waldron et al., 2011). Therefore, having a tool like the LKQ-R could be used to 
assess facts that are known and unknown among new patients.  This tool could be used in the 
medical settings to gather knowledge data at diagnosis and continue to gather follow-up 
knowledge data. Additionally, this could help providers see what dimensions of SLE knowledge 
(cause, timeline, etc.) patients are less knowledgeable of and provide them with additional 
educational material on that specific domain. These findings extend the field by allowing 
clinicians to be able to educate their patients on the reality SLE has on one’s health.  
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 For patients, the future use of the LKQ-R could be used within educational interventions. 
Previous researchers have identified the success of behavioral changes that occur when a 
component of disease-specific information is examined (Cunningham & Kashikar-Zuck, 2013; 
Brown et al., 2012; Ramos-Remus et al., 2000). There had been no systematic way to assess the 
knowledge of SLE, instead, authors created their own assessment variables to examine 
knowledge (Konttinen et al.,1991; Young et al., 2002). The LKQ-R could become an essential 
measurement tool for future SLE interventions research studies that want to assess disease 
knowledge as a variable. Interventions that incorporate an educational aspect of disease have 
shown significant improvements for patients’ mental and physical health experiences (Keefe, 
1996; Keefe, Somers, & Martire, 2008; Evers et al., 2002; Rinaldi et al., 2006; Haupt et al., 
2005). Findings from these previous research studies provide support that with a tool like the 
LKQ-R future interventions can become stronger by examining disease knowledge.   
Conclusion  
The first ever global assessment of SLE awareness was just released to the public in May 
of 2016. The World Lupus Federation conducted a study across 16 countries with 16,911 
participants to determine the public’s awareness and attitudes about SLE (Lupus Foundation of 
America, 2016). The global assessment found that 36% of the participants did not know SLE 
was a disease and 51% did not know that SLE results in severe health complications. The survey 
also found that the misconception surrounding SLE are increasingly believed across the world. 
Knowing that the global misconceptions of SLE are potentially worse than imagined assessing 
accurate rates of knowledge and improving knowledge is a goal to correct the misconceptions.   
The results of this study provided the foundational work that informs a research agenda 
aimed at utilizing the LKQ as a novel assessment tool in SLE research. Through the four 
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developmental phases, there was evidence that the LKQ-R is backed by medical information and 
has the capabilities to identify levels of knowledge participants have of SLE based on their 
education exposure and disease proximity. By creating the LKQ and LKQ-R the first 
examination of community members’ knowledge of SLE was conducted. Furthermore, assessing 
knowledge perceptions provided an additional novel finding related to whether participants have 
actual knowledge or just perceive to have knowledge. Understanding what factors influence 
community members’ knowledge is the first step in creating feasible and informative educational 
interventions aimed to increase SLE awareness and decrease the false stigma associated with 
SLE. 
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Table 1. Frequency of demographic variables Draft LKQ 
Variable N Valid Percentage 
Gender   
Female 192 58 
Male 136 41.1 
Marital Status   
Single, never married  295 88.1 
Married 36 10.7 
Divorced 3 .9 
Race/Ethnicity   
White 278 83 
African American 13 3.9 
Asian 4 1.2 
Latino/a 17 5.1 
Mixed Race 18 5.4 
Pacific Islander 1 .3 
Native American 4 1.2 
Age   
18 21 6.6 
19 31 9.8 
20 35 11.1 
21 65 20.6 
22 59 18.7 
23 42 13.3 
24 63 19.9 
Current Student Enrollment   
High School  14 4.2 
Part-time College  21 6.3 
Full-time College 165 49.1 
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Table 2. Disease Proximity for Sample One 
Have you been diagnosed with 
lupus?  
Frequency Percent Valid 
Percent 
Yes  3 0.9 0.9 
No 328 96.7 99.1 
Prefer not to answer 8 2.4  
Total  336   
 
Do you have an immediate family 
member with lupus?  
Frequency Percent Valid 
Percent 
Yes  8 2.4 2.4 
No 319 94.9 97.6 
Prefer not to answer 9 2.7  
Total  336   
 
Do you have an extended family 
member with lupus? 
Frequency Percent Valid 
Percent 
Yes  14 4.2 4.3 
No 311 92.6 95.7 
Prefer not to answer 11 3.3  
Total  336   
 
Do you know anyone else with 
lupus? 
Frequency Percent Valid 
Percent 
Yes  34 10.1 10.4 
No 293 87.2 89.6 
Prefer not to answer 9 2.7  
Total  336   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
94	
	
Table 3. Description of “Yes” 
Immediate Family Frequency 
Grandmother  1 
In-Law 1 
Sister 1 
Mother 3 
Parent  1 
Omitted 1 
Extended Family Frequency 
Aunt  7 
Cousin 3 
First Cousin 1 
Second Cousin 3 
Other  Frequency 
Friend  10 
Former (colleague, friend, roommate) 4 
Neighbor 2 
 Friends’ parent 2 
Acquaintance 2 
Family friend 1 
Friend of a friend 1 
Colleague 1 
Step dad 1 
Hairdresser 1 
Professor 1 
Significant other of a family member 1 
A celebrity 1 
Program participant 1 
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Table 4. Educational Exposure for Sample One 
Have you heard of SLE?  Frequency Percent Valid 
Percent 
Yes  245 72.9 72.9 
No 91 27.1 27.1 
Total  336   
 
Have you read about SLE? Frequency Percent Valid 
Percent 
Yes  65 19.3 19.4 
No 270 80.4 80.6 
Total  335   
 
Have you attended a lecture on 
SLE? 
Frequency Percent Valid 
Percent 
Yes  6 1.8 1.8 
No 329 97.9 98.2 
Total  336   
 
Have you learned about SLE in a 
class? 
Frequency Percent Valid 
Percent 
Yes  46 13.7 13.7 
No 290 86.3 86.3 
Total  336   
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Table 5. Multiple Regression of Draft Items on Knowledge Scores 
Item B Std. Error Beta t Sign.  
Item 20: Swollen and painful joints are 
symptoms of lupus. 
-.051 .007 -.197 -7.678 .000 
Item 28: Lupus can lead to difficulties with 
memory. 
-.049 .008 -.146 -6.454 .000 
Item 23: Scientists believe that hormones, 
genetics and the environment are all involved 
in causing lupus. 
-.052 .007 -.176 -7.765 .000 
Item 25: Patients are encouraged to minimize 
stressful life events. 
-.037 .006 -.147 -6.015 .000 
Item 9: African Americans are more likely to 
be diagnosed over other racial groups. 
-.035 .008 -.094 -4.514 .000 
Item 13: The degree of symptoms in people 
with lupus is very similar. 
-.036 .009 -.096 -4.088 .000 
Item 33: Certain medications can cause lupus 
symptoms. 
-.039 .008 -.105 -4.705 .000 
Item 7: Men are more likely to be diagnosed 
with lupus than women. 
-.037 .009 -.086 -4.091 .000 
Item 4: Women who have lupus and are 
pregnant are considered to have a "high risk" 
pregnancy. 
-.021 .005 -.085 -4.146 .000 
Item 10: Lupus is a predictable disease. -.027 .010 -.062 -2.815 .005 
Item 34: Lupus can be "caught" by sharing 
personal items with someone who is 
diagnosed 
-.022 .009 -.053 -2.419 .016 
Item 32: People are born with a genetic 
predisposition to getting lupus (more likely to 
have it because of their genetic background). 
-.016 .007 -.051 -2.342 .020 
Item 16: Being diagnosed with lupus places an 
individual at greater risk for additional 
medical diagnoses. 
.002 .001 .039 2.296 .022 
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Table 6. Item Difficulty, Item Correlation, Readability of Draft Version 
Item Item 
Difficulty 
With All (N) 
Item 
Difficulty 
w/o DKs 
(N) 
Item- 
total 
Corr. 
Flesch 
Reading 
Ease 
Flesch-
Kincaid 
Reading 
Level 
Item 1: Fatigue 0.295 (336) 0.733 (135) 0.630 42.6 9.0 
Item 2: Immune count test 0.027 (335) 0.145 (62) 0.333 74.8 5.8 
Item 3: Heart disease 0.171 (332) 0.877 (65) 0.575 --- 16.5 
Item 4: High risk pregnancy 0.298 (336) 0.944 (106) 0.562 67.5 7.5 
Item 5: Steroid medication 0.147 (334) 0.817 (60) 0.542 29.5 11.1 
Item 6: Digestive issues 0.123 (334) 0.732 (56) 0.575 47.5 10.0 
Item 7: Men diagnosed more 0.158 (336) 0.768 (69) 0.597 72.6 5.8 
Item 8: Same virus 0.122 (335) 0.804 (51) 0.484 95.9 2.8 
Item 9: AA disparity 0.137 (336) 0.596 (52) 0.472 32.5 11.7 
Item 10: Predictable disease 0.217 (336) 0.859 (85) 0.701 32.5 9.9 
Item 11: Single gene 0.081 (335) 0.614 (44) 0.515 69.7 6.0 
Item 12: Skin rashes 0.230 (335) 0.917 (84) 0.680 73.8 4.4 
Item 13: Symptom similarities 0.182 (336) 0.693 (88) 0.728 57.2 8.0 
Item 14: Risk of more diagnoses 0.230 (335) 0.917 (84) 0.707 17.3 14.3 
Item 15: Aging 0.089 (336) 0.476 (63) 0.554 34.5 9.1 
Item 16: Multiple diagnoses 0.188 (335) 0.940 (67) 0.667 42.6 9.0 
Item 17: Jaundice 0.051 (334) 0.283 (60) 0.379 64.9 6.9 
Item 18: Great Imitator 0.200 (335) 0.944 (71) 0.731 37.4 11.2 
Item 19: Symptoms begin soon 0.188 (335) 0.887 (71) 0.698 42.6 9.0 
Item 20: Swollen/painful joints 0.265 (336) 0.927 (96) 0.755 71.8 5.2 
Item 21: Negative impact on work 0.232 (336) 0.788 (99) 0.699 47.8 10.5 
Item 22: Treatment can cure 0.266 (335) 0.937 (95) 0.731 75.8 3.6 
Item 23: Hormone, gene, envt. 0.182 (336) 0.871 (70) 0.675 41.5 10.9 
Item 24: Hair loss 0.199 (336) 0.763 (59) 0.501 90.9 2.3 
Item 25: Minimize stressful events 0.300 (336) 0.971 (104) 0.737 40.0 9.6 
Item 26: Specific cause know 0.149 (335) 0.820 (61) 0.718 49.5 9.0 
Item 27: Distinguish b/w cells 0.209 (335) 0.921 (76) 0.755 44.9 10.7 
Item 28: Memory difficulties 0.134 (336) 0.804 (56) 0.638 42.6 9.0 
Item 29: Treatment stand/similar 0.141 (334) 0.758 (62) 0.675 64.9 6.9 
Item 30: No exercising 0.104 (336) 0.761 (46) 0.530 17.9 13.9 
Item 31: Kidney disease 0.054 (334) 0.419 (43) 0.440 61.3 7.1 
Item 32: Genetic predisposition 0.158 (336) 0.855 (62) 0.562 42.7 12.2 
Item 33: Meds cause symptoms 0.098 (336) 0.611 (54) 0.531 31.5 10.3 
Item 34: “Catching” lupus 0.265 (336) 0.881 (101) 0.683 50.4 9.4 
Item 35: Sensitivity to the sun 0.164 (335) 0.859 (64) 0.662 52.8 8.3 
Item 36: Bipolar diagnosis 0.080 (336) 0.563 (48) 0.476 10.5 14.2 
Item 37: Resolved skin rash 0.143 (335) 0.828 (58) 0.684 60.7 7.7 
Item 38: Common for Caucasians 0.066 (335) 0.458 (48) 0.368 26.6 13.5 
Overall   0.960 49.3 8.9 
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Table 7. Frequencies of LKQ-Draft Responses 
 Item Correct 
Response 
Answered 
Correctly 
Answered 
Incorrectly 
(w/o DKs) 
Answered 
Don’t Know 
1 Fatigue is rarely experienced for lupus 
patients.  
False 99(29.5%) 36 (10.7%) 201(59.8%) 
2 The “immune count test” is the one used 
for diagnosing lupus. 
False 9(2.7%) 53(15.8%) 273(81.3) 
3 Lupus increases an individual’s risk of 
premature cardiovascular disease (heart 
disease) 
True 57(17.0%) 8(2.4%) 267 (79.5%) 
4 Women who have lupus and are 
pregnant are considered to have a “high 
risk” pregnancy. 
True 100 (29.8%) 6(1.8%) 230(68.5) 
5 Steroid medication has the fewest 
negative side effects. 
False 49(14.6%) 11(3.3%) 274(81.5%) 
6 Patients with lupus experience more 
digestive issues, causing them to need to 
use the restrooms more often. 
True 41(12.2%) 15(4.5%) 278(82.7%) 
7 Men are more likely to be diagnosed 
with lupus than women. 
False 53(15.8%) 16(4.8%) 267(79.5%) 
8 Lupus us caused by the same virus that 
is linked to HIV. 
False 41(12.2%) 10(3.0%) 284(84.5%) 
9 African Americans are more likely to be 
diagnosed over other racial groups. 
True 31(9.2%) 21(6.3%) 284(84.5%) 
10 Lupus is a predictable disease. False 73(21.7%) 12(3.6%) 251(74.7%) 
11 Scientists believe there is a single gene 
that causes lupus. 
False 27(8.0%) 17(5.1%) 291(86.6%) 
12 Skin rashes are symptoms of lupus. True 77(22.9%) 7(2.1%) 251(74.7%) 
13 The degrees of symptoms in people with 
lupus are very similar.  
False 61(18.2%) 27(8.0%) 248(73.8%) 
14 Being diagnosed with lupus places an 
individual at greater risk for additional 
medical diagnoses. 
True 77(22.9%) 7(2.1%) 251(74.7%) 
15 Aging triggers lupus. False 30(8.9%) 33(9.8%) 273(81.3%) 
16 There are multiple types of lupus 
diagnoses. 
True 63(18.8%) 4(1.2%) 267(79.5%) 
17 Yellowing of the skin (jaundice) is a 
common symptom of lupus. 
False 17(5.1%) 43(12.8%) 274(81.5%) 
18 Lupus is often called “the great imitator” 
because lupus mimics other health 
conditions. 
True 67(19.9%) 4(1.2%) 264(78.6%) 
19 Lupus is diagnosed soon after symptoms 
begin. 
False 63(18.8%) 8(2.4%) 264(78.6%) 
20 Swollen and painful joints are symptoms 
of lupus. 
True 89(26.5%) 7(2.1%) 240(71.4%) 
21 A diagnosis of lupus does not have a 
negative impact on a person’s ability to 
work. 
False 78(23.2) 21(6.3%) 237(70.5%) 
22 Treatment can cure lupus. False 89(26.5%) 6(1.8%) 240(71.4%) 
23 Scientists believe that hormones, 
genetics, and the environment are all 
involved in causing lupus. 
True 61(18.2%) 9(2.7%) 266(79.2%) 
24 Hair loss is a symptom of lupus. True 45(13.4%) 14(4.2%) 277(82.4%) 
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25 Patients are encouraged to minimize 
stressful life events.  
True 101(30.1%) 3(0.9%) 232(69.0%) 
26 The specific cause of lupus has been 
identified by research scientist. 
False 50(14.9%) 11(3.3%) 274(81.5%) 
27 The immune system of someone with 
lupus cannot distinguish between healthy 
cells and harmful cells. 
True 70(20.8%) 6(1.8%) 259(77.1%) 
28 Lupus can lead to difficulties with 
memory. 
True 45(13.4%) 11(3.3%) 280(83.3%) 
29 Treatment plans for lupus have been 
standardized and are similar. 
False 47(14.0%) 15(4.5%) 272(81.0%) 
30 Patients are encouraged to not exercise 
following diagnosis to help control 
disease progression. 
False 35(10.4%) 11(2.2%) 290(86.3%) 
31 Kidney disease is one of the first 
indicators of lupus. 
False 18(5.4%) 25(7.4%) 291(86.6%) 
32 People are born with a genetic 
predisposition to getting lupus (more 
likely to have it because of their genetic 
background). 
True 53(15.8%) 9(2.7%) 274(81.5%) 
33 Certain medications can cause lupus 
symptoms. 
True 33(9.8%) 21(6.3%) 282(83.9%) 
34 Lupus can be “caught” by sharing 
personal items with someone who is 
diagnosed. 
False 89(26.5%) 12(3.6%) 235(69.9%) 
35 Sensitivity to the sun is a concern for 
lupus patients.  
True 55(16.4%) 9(2.7%) 271(80.7%) 
36 Bipolar disorder is the most common co-
occurring mental health diagnosis. 
False 27(8.0%) 21(6.3%) 288(85.7%) 
37 Lupus skin rashes that occur can be 
resolved easily with skin lotion. 
False 48(14.3%) 10(3.0%) 277(82.4%) 
38 Lupus is more common for Caucasians 
than for individuals of Hispanic, Asian, 
and Native American descent.  
False 22(6.5%) 26(7.7%) 287(85.4%) 
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Table 8. Frequency of Sample Two demographic variables  
Variable N Valid Percentage 
Gender   
Female 144 77.8 
Male 41 22.2 
Marital Status   
Married 137 73.3 
Single, never married 32 17.1 
Divorced 16 8.6 
Race/Ethnicity   
White 154 83.2 
African American 10 5.4 
Asian 3 1.6 
Latino/a 8 4.3 
Mixed Race 7 3.8 
Middle Eastern 1 0.5 
Native American 2 1.1 
Age   
20-24 13 7.1 
25-29 37 21.0 
30-34 67 36.7 
35-39 41 22.4 
40-44 17 9.2 
45-49 5 2.6 
50-54 3 1.6 
Years of Education   
12 (HS graduate) 16 8.6 
13 25 13.4 
14 (Associate Degree) 23 12.4 
15 12 6.5 
16 (Bachelor Degree) 63 33.9 
17 4 2.2 
18(Master Degree) 24 12.9 
19 5 2.7 
20 (Doctorate/Professional Degree) 14 7.5 
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Table 9. Disease Proximity for Sample Two  
Have you been diagnosed with 
lupus?  
Frequency Percent Valid 
Percent 
Yes  3 1.6 1.6 
No 182 97.3 98.4 
Total  186   
 
Do you have an immediate family 
member with lupus?  
Frequency Percent Valid 
Percent 
Yes  4 2.1 2.2 
No 182 96.8 97.8 
Total  186   
 
Do you have an extended family 
member with lupus? 
Frequency Percent Valid 
Percent 
Yes  18 9.6 9.7 
No 168 89.4 90.3 
Total  186   
 
Do you know anyone else with 
lupus? 
Frequency Percent Valid 
Percent 
Yes  48 25.5 25.8 
No 138 73.4 74.2 
Total  186   
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Table 10. Description of “Yes” 
Immediate Family Frequency 
Mother 2 
Omitted 2 
Extended Family Frequency 
Aunt  2 
Cousin 6 
Aunts and Cousins* 1 
Great Aunt 1 
Husband’s Uncle 1 
Husband’s Cousin 1 
Paternal Aunt 2 
Paternal Great-Grandmother 1 
Through Marriage 1 
Step Father-in-law 1 
Other  Frequency 
Friend  24 
Former (colleague/friend) 2 
Childhood/high school Friend 2 
 Friends’ grandparent 1 
Acquaintance 4 
Family friend 3 
Co-worker/Colleague 2 
Friend, coworker, underwent testing 
myself** 
1 
Child’s former teacher 1 
Neighbor 1 
Job Patient 1 
*Cannot infer further, remains as an answer of 1   
** Cannot infer further, remains an answer of 1 
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Table 11. Educational Exposure for Sample Two  
Have you heard of SLE?  Frequency Percent Valid 
Percent 
Yes  179  72.9 
No 9 27.1 27.1 
Total  188   
 
Have you read about SLE? Frequency Percent Valid 
Percent 
Yes  84 44.7 44.7 
No 104 55.3 55.3 
Total  188   
 
Have you attended a lecture on 
SLE? 
Frequency Percent Valid 
Percent 
Yes  6 3.2 3.2 
No 181 96.3 98.8 
Total  187   
 
Have you learned about SLE in a 
class? 
Frequency Percent Valid 
Percent 
Yes  24 12.8 12.8 
No 163 86.7 87.2 
Total  187   
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Table 12. Item Difficulty, Item Discrimination, Item Correlation, Readability of Revised Version 
Item Item 
Difficulty 
With All 
(N) 
Item 
Discrim. 
Item-
total 
Corr. 
Flesch 
Reading 
Ease 
Flesch-
Kincaid 
Reading 
Level 
Item 1: Swollen/painful joints 0.643(188) 74.6 0.626 71.8 5.2 
Item 2: Memory Difficulties 0.316(187) 62.7 0.476 42.6 9.0 
Item 3: Horm, Envir, Gene 0.380(187) 70.6 0.589 46.6 9.7 
Item 4: Minimize stress 0.586(186) 74.4 0.662 40.0 9.6 
Item 5: AA disparity 0.342(187) 46.2 0.400 32.5 11.7 
Item 6: Symptoms Similar 0.388(188) 62.7 0.560 57.2 8.0 
Item 7:Distingusih Cells 0.583(187) 84.1 0.707 44.9 10.7 
Item 8: Medications cause 0.255(188) 51.0 0.447 31.5 10.3 
Item 9: Men diagnosed more 0.319(188) 70.6 0.563 72.6 5.8 
Item 10: High risk pregnancy 0.473(188) 68.6 0.575 67.5 7.5 
Item 11: Predictable  0.535(185) 75.9 0.622 32.5 9.9 
Item 12: Spread by sharing 0.706(187) 52.2 0.609 50.4 9.4 
Item 13: Genetic predisposition 0.404(188) 45.1 0.446 45.0 11.6 
Item 14: Risk of more diagnoses 0.535(187) 85.1 0.743 17.3 12.0 
Item 15: Premature heart disease 0.251(187) 54.9 0.477 ** 12.0 
Item 16: Fatigue  0.606(188) 58.9 0.605 42.6 9.0 
Item 17: Severity is similar 0.489(188) 66.7 0.608 29.5 11.1 
Item 18: Great Imitator 0.468(188) 78.4 0.658 37.4 11.2 
Item 19: Hair loss/thinning 0.439(187) 84.2 0.616 82.3 3.7 
Item 20: Validity Item 1.00 (188) --- --- --- --- 
Item 21: Skin rash 0.428(187) 64.3 0.560 73.8 4.4 
Item 22: Sensitivity to sun 0.441(188) 70.6 0.595 52.8 8.3 
Item 23: Immune count test 0.048(188) 11.7 0.246 74.8 5.8 
Item 24: Years to diagnose 0.484(188) 66.7 0.593 66.1 6.2 
Item 25: Immune system weak 0.711(187) 66.6 0.710 66.1 6.2 
Item 26: Diagnose soon  0.380(187) 58.7 0.557 42.6 9.0 
Item 27: Bipolar most common 0.128(188) 29.4 0.361 17.9 12.0 
Item 28: Caucasians more 0.188(186) 43.1 0.403 26.6 12.0 
Item 29: Take years to diagnose 0.495(188) 74.5 0.671 66.1 6.2 
Item 30: Aging triggers 0.085(188) 13.7 0.185 34.5 9.1 
Item 31: Kidney disease 0.085(188) 18.7 0.272 61.3 7.1 
Item 32: Jaundice symptom 0.107(187) 20.1 0.256 64.9 6.9 
Item 33: Multiple diagnoses 0.351(188) 60.8 0.523 42.6 9.0 
Item 34: Treatment can cure 0.510 (188) 70.6 0.593 75.8 3.6 
Overall   0.940 49.6 8.7 
--indicates the item was not analyzed 
** item exceeded the score range 
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Table 13. Frequencies of LKQ-Revised Responses 
 Item Correct 
Response 
Answered 
Correctly 
Answered 
Incorrectly 
(w/o DKs) 
Answered 
Don’t Know 
1 Swollen and painful joints are symptoms of 
lupus. 
True 121(64.4%) 2(1.1%) 65(34.6%) 
2 Lupus can lead to difficulties with memory. True 59(31.6%) 12(6.4%) 116(62.0%) 
3 The onset of lupus is triggered by 
hormones, genetics and the environment. 
True 71(38.0%) 9(4.8%) 107 (56.2%) 
4 Patients are encouraged to minimize 
stressful life events. 
True 109(58.6%) 4(2.2%) 73(39.2%) 
5 African Americans are more likely to be 
diagnosed over other racial groups. 
True 64(34.2%) 15(8.0%) 108(57.8%) 
6 The degree of symptoms in people with 
lupus is very similar. 
False 73(38.8%) 29(15.4%) 86(45.7%) 
7 The immune system, of someone with 
lupus, cannot distinguish between healthy 
cells and harmful cells. 
True 109(58.3%) 2(1.1%)     76(40.6%) 
8 Certain medications can cause lupus 
symptoms. 
True 48(25.5%) 19(10.1%) 121(64.4%) 
9 Men are more likely to be diagnosed with 
lupus than women. 
False 60(31.9%) 9(4.8%) 119(63.3%) 
10 Women who have lupus and are pregnant 
are considered to have a high risk 
pregnancy. 
True 89(47.3%) 6(3.2%) 93(49.5%) 
11 Lupus is a predictable disease. False 99(53.5%) 9(4.9%) 77(41.6%) 
12 Lupus can be spread by sharing personal 
items with someone who is diagnosed. 
False 132(70.6%)  9(4.8%) 46(24.6%) 
13 People are born with a genetic 
predisposition for lupus (more likely to 
have it because of their genetic 
background). 
True 76(40.4%) 8(4.3%) 104(55.3%) 
14 Being diagnosed with lupus places an 
individual at greater risk for additional 
medical diagnoses. 
True 100(53.5%) 1(0.5%) 86(46.0%) 
15 Lupus increases an individuals’ risk of 
premature cardiovascular disease (heart 
disease). 
True 47(25.1%) 6(3.2%) 134(71.7%) 
16 Fatigue is rarely experienced for lupus 
patients. 
False 114(60.6%) 25(13.3%) 49(26.1%) 
17 The severity of symptoms is similar across 
patients. 
False 92(48.9%) 20(10.6%) 76(40.4%) 
18 Lupus is often called the great imitator 
because lupus mimics other health 
conditions. 
True 88(46.8%) 4(2.1%) 96(51.1%) 
19 Hair loss/thinning is a symptom of lupus. True 82(43.9%) 6(3.2%) 99(52.9%) 
20 Please answer true for this item.  True 188(100%) --- --- 
21 Skin rashes are symptoms of lupus. True 80(42.8%) 5(2.7%) 102(54.5%) 
22 Sensitivity to the sun is a concern for lupus 
patients. 
True 83(44.1%) 5(2.7%) 100(53.2%) 
23 The immune count test is the one test used 
for diagnosing lupus. 
False 9(4.8%)      45(23.9%) 134(71.3%) 
24 It may take many years to confirm a 
diagnosis. 
True 91(48.4%) 7(3.7%) 90(47.9%) 
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25 The immune system of patients with lupus 
is weakened. 
True 133(71.1%) 5(2.7%) 49(26.2%) 
26 Lupus is diagnosed soon after symptoms 
begin. 
False 71(38.0%) 18(9.6%) 98(52.4%) 
27 Bi-polar disorder is the most common co-
occurring mental health diagnosis for lupus 
patients. 
False 24(12.8%) 19(10.1%) 145(77.1%) 
28 Lupus is more common for Caucasians than 
for individuals of Hispanic, Asian, and 
Native American decent. 
False 35(18.8%) 20(10.8%) 131(70.4%) 
29 It may take many years to confirm a 
diagnosis. 
True 93(49.5%) 5(2.7%) 90(47.9%) 
30 Aging triggers lupus. False 16(8.5%) 23(12.2%) 149(79.3%) 
31 Kidney disease is one of the first indicators 
of lupus. 
False 16(8.5%) 23(12.2%) 149(79.3%) 
32 Yellowing of the skin (jaundice) is a 
common symptom of lupus. 
False 20(10.7%) 30(16.0%) 137(73.3%) 
33 There are multiple types of lupus diagnoses. True 66(35.1%) 11(5.9%) 111(59.0%) 
34 Treatment can cure lupus. False 96(51.1%) 7(3.7%) 85(45.2%) 
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APPENDIX A: 
 
Medical provider Interview Protocol 
 
A. Introduction 
1. Thanks for coming- brief explanation of the protocol. This should take no longer 
than 60 minutes. Describe importance of information they are providing-You are 
part of a critical phase of developing the first ever lupus knowledge questionnaire 
to assess both patients’ disease knowledge and knowledge of SLE among the 
general public. 
2. Explain and read (provide) Informed Consent and then they will be asked to 
complete a demographic survey on my laptop through Qualtrics.  
B. Purpose 
1. I want the questionnaire to be physician and patient driven which is why I want to 
hear about your experiences with living with lupus.  
2. I want to know about your ideas, suggestions and comments about what questions 
and content should be included in an SLE knowledge questionnaire. As you are a 
medical professional who has had experience providing patients with information 
related to lupus you know what questions are asked or what should be asked.  I 
want to use that and your medical background to understand how I can create a 
useful questionnaire.  
C. Procedure 
1. Session will be recorded- This is all confidential, your name will not be collected with your 
responses. Anything you say here is only used for the purpose of my research and the LKQ.   
 
Begin – turn on recorder  
For the first set of questions, I’m going to ask you about your experiences with patients and your 
thoughts on the type of knowledge they want to gain, the type of knowledge you think they should 
have, and any misconceptions they have about SLE. For the second set of questions, I’m going to 
ask you about the resources you provide to patients. And finally, for the third set of questions, 
I’m going to ask you about knowledge you think would be useful for family members or those 
caring for people with SLE to have, as well as people within the general public.  
 
1. Tell me a little bit about your medical background and the types of conditions you see in 
patients? 
 
SET 1: Thoughts on the type of knowledge you think patients should have 
 
2. What information do you think is important for patients to know? 
a) What are some specific questions related to the cause of SLE that would be 
beneficial to assess in a knowledge questionnaire? (E.g. SLE is caused by 
smoking – T/F)  
b) What are some specific questions related to the symptoms that occur in SLE that 
would be beneficial to assess? (E.g. Groups of symptoms of SLE are often times 
described as flares- T/F) 
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c) What are some specific questions related to the course of SLE that would be 
beneficial to assess? (E.g. The average length of time it takes to receive a 
diagnosis is 5 years –T/F) 
d) What are some specific questions related to the controllability of SLE that would 
be beneficial to assess? (E.g. Medication use? Exercise? Eating habits?)  
e) What are some specific questions related to the chronic style of SLE that would 
be beneficial to assess? (E.g. Longevity? Quality of life?)  
 
3. What misconceptions do patients tend to have about their diagnosis? 
4. What questions regarding SLE do patients not ask about that they should? 
 
SET 2: The resources used to educate patients  
 
1. How do you educate patients about SLE? 
a) Prompt:  Could you explain what you say to someone who is diagnosed and walk 
me through your explanation of the disease?  
2. What resources do you provide them? 
a) Prompt: Pamphlets, handouts (from where) or reliable internet sources (from where) 
1. What has been your experience with this?  
2. How well does this or does this not work?  
3. What resources do you have at your disposal to assist you in providing 
education/knowledge to your SLE patients? (If not already answered from the above 
question)  
4. What other resources (if any) would be helpful to have at your disposal when trying to educate 
patients?  
5. Are there any resources that you find counter-productive? For instance, are there are websites that 
give patients an unrealistic view of the disease? 
 
SET 3: Useful for family members/caregivers/general public to have 
 
1. What should people know about SLE to have a good general understanding of the illness and how 
it is experienced by people? (i.e. causes, symptoms, treatment, etc.)  (Not patients)  
2. What information do you think is important for family members or caretakers of patients to 
know? 
3. What misconceptions do you think the general public tends to have about the diagnosis? 
4. Any other thoughts, comments or suggestions before we conclude the interview. 
 
THANK YOU! After I compile all of the information from these interviews I will create a draft 
of the LKQ. Once the draft has been created I would like to contact you and get some feedback 
on the questions before I begin testing it within patient and community samples. Would you be 
okay with this?  
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APPENDIX B: 
Materials for Medical Provider Verification 
Here you will be asked to read over the lupus knowledge questionnaire draft and provide a 
relevance score for each item (1= not relevant/exclude to 4= highly relevant/keep as is). After 
providing a 1-4 score for each item then you will be asked to provide feedback on clarity and 
accuracy. This will give you the opportunity to provide edits or comments related to that item.  
Relevance: Is the item relevant to be involved in a general SLE-specific disease knowledge?  
Clarity: Is the item clear in regard to the wording?  
Accuracy: Does the item contain accurate medical information?  
 
If you indicate a 2 or a 3 please provide recommendations or alterations that could be 
added to make the question be rated a 4. 
***** 
This questionnaire will be given to a community sample of individuals for initial testing. 
Therefore, it is meant to be a more generalist questionnaire rather than specific details for 
patients or providers.
 
 
110	
	
 
 Item on the lupus knowledge questionnaire (LKQ) Relevance 
1  Hair loss is a symptom of lupus –ANS: T  
Do you have any changes that you would like to see applied in terms of accuracy or clarification of 
the item? Add any comments or edits below.  
 
2 Skin rashes are symptoms of lupus–ANS: T  
Do you have any changes that you would like to see applied in terms of accuracy or clarification of 
the item? Add any comments or edits below.  
 
3 Sensitivity to the sun is a concern for lupus patients–ANS: T  
Do you have any changes that you would like to see applied in terms of accuracy or clarification of 
the item? Add any comments or edits below.  
 
4 Swollen and painful joints are symptoms of lupus–ANS: T  
Do you have any changes that you would like to see applied in terms of accuracy or clarification of 
the item? Add any comments or edits below.  
 
5 Yellowing of the skin (jaundice) is a common symptom of 
lupus–ANS: F 
 
Do you have any changes that you would like to see applied in terms of accuracy or clarification of 
the item? Add any comments or edits below.  
 
6 Kidney disease is one of the first indicators of lupus–ANS: F  
Do you have any changes that you would like to see applied in terms of accuracy or clarification of 
the item? Add any comments or edits below.  
 
7 The degree of symptoms in people with lupus are very similar–
ANS: F 
 
Do you have any changes that you would like to see applied in terms of accuracy or clarification of 
the item? Add any comments or edits below.  
 
8 Fatigue is rarely experienced for lupus patients–ANS: F  
Do you have any changes that you would like to see applied in terms of accuracy or clarification of 
the item? Add any comments or edits below.  
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9 Lupus is often called “the great imitator” because lupus mimics 
other health conditions–ANS: T 
 
Do you have any changes that you would like to see applied in terms of accuracy or clarification of 
the item? Add any comments or edits below.  
 
10 Lupus is diagnosed soon after symptoms begin–ANS: F  
Do you have any changes that you would like to see applied in terms of accuracy or clarification of 
the item? Add any comments or edits below.  
 
11 The “immune count test” is the one test used for diagnosing 
lupus–ANS: F 
 
Do you have any changes that you would like to see applied in terms of accuracy or clarification of 
the item? Add any comments or edits below.  
 
12 The immune system, of someone with lupus, cannot distinguish 
between healthy cells and harmful cells–ANS: T 
 
Do you have any changes that you would like to see applied in terms of accuracy or clarification of 
the item? Add any comments or edits below.  
 
13 Men are more likely to be diagnosed with lupus than women–
ANS: F 
 
Do you have any changes that you would like to see applied in terms of accuracy or clarification of 
the item? Add any comments or edits below.  
 
14 Lupus is caused by the same virus that is linked to HIV–ANS: F  
Do you have any changes that you would like to see applied in terms of accuracy or clarification of 
the item? Add any comments or edits below.  
 
15 Scientists believe there is a single gene that causes lupus–ANS: 
F 
 
Do you have any changes that you would like to see applied in terms of accuracy or clarification of 
the item? Add any comments or edits below.  
 
16 African Americans are more likely to be diagnosed over other 
racial groups–ANS: T 
 
Do you have any changes that you would like to see applied in terms of accuracy or clarification of 
the item? Add any comments or edits below.  
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17 The specific cause of lupus has been identified by research 
scientists–ANS: F 
 
Do you have any changes that you would like to see applied in terms of accuracy or clarification of 
the item? Add any comments or edits below.  
 
18 People are born with a genetic predisposition to getting lupus 
(more likely to have it because of their genetic background) –
ANS: T 
 
Do you have any changes that you would like to see applied in terms of accuracy or clarification of 
the item? Add any comments or edits below.  
 
19 Scientists believe that hormones, genetics, and the environment 
are all involved in causing lupus–ANS: T 
 
Do you have any changes that you would like to see applied in terms of accuracy or clarification of 
the item? Add any comments or edits below.  
 
20 Aging triggers lupus–ANS: F  
Do you have any changes that you would like to see applied in terms of accuracy or clarification of 
the item? Add any comments or edits below.  
 
21 There are multiple types of lupus diagnoses–ANS: T  
Do you have any changes that you would like to see applied in terms of accuracy or clarification of 
the item? Add any comments or edits below.  
 
22 Certain medications can cause lupus symptoms –ANS: T  
Do you have any changes that you would like to see applied in terms of accuracy or clarification of 
the item? Add any comments or edits below.  
 
23 Lupus can be “caught” by sharing personal items with someone 
who is diagnosed–ANS: F 
 
Do you have any changes that you would like to see applied in terms of accuracy or clarification of 
the item? Add any comments or edits below.  
 
24 Lupus is more common for Caucasians than for individuals of 
Hispanic, Asian, and Native American decent–ANS: F 
 
Do you have any changes that you would like to see applied in terms of accuracy or clarification of 
the item? Add any comments or edits below.  
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25 Treatment can cure lupus–ANS: F  
Do you have any changes that you would like to see applied in terms of accuracy or clarification of 
the item? Add any comments or edits below.  
 
26 Treatment plans for lupus have been standardized and are all 
similar–ANS: F 
 
Do you have any changes that you would like to see applied in terms of accuracy or clarification of 
the item? Add any comments or edits below.  
 
27 Steroid medication has the fewest negative side effects–ANS: F  
Do you have any changes that you would like to see applied in terms of accuracy or clarification of 
the item? Add any comments or edits below.  
 
28 Lupus is a predictable disease–ANS: F  
Do you have any changes that you would like to see applied in terms of accuracy or clarification of 
the item? Add any comments or edits below.  
 
29 Patients are encouraged to not exercise following diagnosis to 
help control disease progression–ANS: F 
 
Do you have any changes that you would like to see applied in terms of accuracy or clarification of 
the item? Add any comments or edits below.  
 
30 Being diagnosed with lupus places an individual at greater risk 
for additional medical diagnoses–ANS: T 
 
Do you have any changes that you would like to see applied in terms of accuracy or clarification of 
the item? Add any comments or edits below.  
 
31 Patients are encouraged to minimize stressful life events–ANS: T  
Do you have any changes that you would like to see applied in terms of accuracy or clarification of 
the item? Add any comments or edits below.  
 
32 Bi-polar disorder is the most common co-occurring mental 
health diagnosis–ANS: F 
 
Do you have any changes that you would like to see applied in terms of accuracy or clarification of 
the item? Add any comments or edits below.  
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33 Women who have lupus and are pregnant are considered to have 
a “high risk” pregnancy–ANS: T 
 
Do you have any changes that you would like to see applied in terms of accuracy or clarification of 
the item? Add any comments or edits below.  
 
34 Lupus skin rashes that occur can be resolved easily with skin 
lotion–ANS: F 
 
Do you have any changes that you would like to see applied in terms of accuracy or clarification of 
the item? Add any comments or edits below.  
 
35 Lupus can lead to difficulties with memory–ANS: T  
Do you have any changes that you would like to see applied in terms of accuracy or clarification of 
the item? Add any comments or edits below.  
 
36 Patients with lupus experience more digestive issues, causing 
them to need restrooms more often–ANS: T 
 
Do you have any changes that you would like to see applied in terms of accuracy or clarification of 
the item? Add any comments or edits below.  
 
37 A diagnosis of lupus does not have a negative impact on a 
person’s ability to work–ANS: F 
 
Do you have any changes that you would like to see applied in terms of accuracy or clarification of 
the item? Add any comments or edits below.  
 
38 Lupus increases an individual’s risk of premature cardiovascular 
disease (heart disease) –ANS: T 
 
Do you have any changes that you would like to see applied in terms of accuracy or clarification of 
the item? Add any comments or edits below.  
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APPENDIX C: 
Demographic and Educational Exposure/ Disease Proximity Questions 
Instructions: Fill out all demographic items below as honestly as possible. Please fill in boxes or 
type responses when necessary. Please read all of the directions before continuing though the 
survey. 
 
1) What gender do you identify with? 
• Female 
• Male 
• Other (please specify) ____________________ 
 
2) With which race and/or ethnicity do you identify (select all that apply) 
• Asian  
• Pacific Islander 
• Black/African American 
• Hispanic/Latino/a 
• Native American  
• White/Caucasian 
• Mixed 
 
3) What is your current age? _____ 
 
4) Are you currently a student? 
• Yes, high school 
• Yes, part-time college  
• Yes, full-time college 
• No 
 
5) What is your marital status? 
• Single (never married) 
• Married 
• Separated 
• Divorced 
 
6) How many years of education do you have? ______ 
 
(Educational exposure Items) 
 Yes No 
1. Have you heard of SLE? m  m  
2. Have you read about SLE? m  m  
3. Have you attended a lecture about SLE? m  m  
4. Have you learned able SLE in a class?  m  m  
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How confident are you in the accuracy of your current knowledge about SLE? 
 Not 
Confident 
Somewhat 
Confident 
N/A or 
Unsure 
Confidence 
Confident Extremely 
Confident 
Lupus m  m  m  m  m  
 
(Disease Proximity Items) 
You may choose to leave these items blank if you are not comfortable disclosing. Please 
consider responding if you are comfortable. Your responses are confidential.  
 
a) Have you been diagnosed with Lupus? ____ Yes _____No 
b) Do you have an immediate family member diagnosed with Lupus? ___Yes   ___ No 
c) Has anyone in your extended family ever been diagnosed with Lupus? __Yes ___No 
d) Do you know anyone else who has been diagnosed with Lupus? ___ Yes ____ No  
 
*** LKQ will appear here*** 
Following completion of the questionnaire participants will be asked to complete these final two items. 
 
 
How well do you believe you did on the task above? (0= I did not get any items correct, 100= I 
got all the items correct.) 
0%_______________100% 
 
Based on your knowledge of lupus how do you believe you compare to the average person? 
m I have more knowledge than the average person 
m I have some more knowledge than the average person 
m I am the same as the average person 
m I have less knowledge than the average person 
m I know nothing compared to the average person 
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APPENDIX D: 
CVI Verification Feedback from Providers 
 Original P1 
score 
P1 edits P2 
score 
P2 edits P3 
score 
P3 edits Agree 
Rate 
1 a  Hair loss is a 
symptom of 
lupus  
4 hair loss or 
thinning hair 
 
4  3  100% 
2 a Skin rashes are 
symptoms of 
lupus 
4 Butterfly rash 
across bridge of 
nose and cheeks. 
4  3  100% 
3 a Sensitivity to 
the sun is a 
concern for 
lupus patients 
3  4  4  100% 
4 ab Swollen and 
painful joints 
are symptoms 
of lupus 
4 Patients usually 
complain of joint 
stiffness and pain 
that does not 
resolve after 
activity. 
4  2  67% 
5 c Yellowing of 
the skin 
(jaundice) is a 
common 
symptom of 
lupus 
1  4 Generally not 
true unless has 
hepatitis with 
the disease 
false 
1  33% 
6 a Kidney disease 
is one of the 
first indicators 
of lupus 
1  4 I cannot agree-
false 
 
3  67% 
7 ab The degree of 
symptoms in 
people with 
lupus are very 
similar 
2 /4** 
 
 
People are 
individually 
affected by this 
disease in 
different ways. 
Some people 
have more severe 
symptoms while 
others have less 
severe 
symptoms. 
4 not true- false 
 
1  67% 
8 a Fatigue is rarely 
experienced for 
lupus patients 
4 One of the first 
complaints of 
patient 
presenting with 
lupus signs is 
generalized 
fatigue. 
4 false 4  100% 
9 a Lupus is often 
called “the great 
imitator” 
because lupus 
mimics other 
4  3  3  100% 
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health 
conditions 
10 a  Lupus is 
diagnosed soon 
after symptoms 
begin 
1/4 ** 
 
It may take many 
years for the 
affirmative of the 
diagnosis. 
 
4 false 1  67% 
11 a The “immune 
count test” is 
the one test 
used for 
diagnosing 
lupus 
1  4 false 3  67% 
12 a The immune 
system, of 
someone with 
lupus, cannot 
distinguish 
between healthy 
cells and 
harmful cells 
4 Patients with 
lupus usually 
have a weakened 
immune system 
than others. 
 
4 not true- it is 
the 
autoantibodies 
 
2  67% 
13 b Men are more 
likely to be 
diagnosed with 
lupus than 
women 
1  4  1  33% 
14 d Lupus is caused 
by the same 
virus that is 
linked to HIV 
1  2  1  0% 
15 d Scientists 
believe there is 
a single gene 
that causes 
lupus 
1  2  1  0% 
16 ab African 
Americans are 
more likely to 
be diagnosed 
over other racial 
groups 
4  4 I would have 
thought 
otherwise-
Incidence 
maybe higher-
but due to 
economic 
factors and 
access to 
decent care-
they are less 
likely to be 
diagnosed 
earlier. 
3  100% 
17 d The specific 
cause of lupus 
has been 
identified by 
research 
scientists 
1  4  1  33% 
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18 ab People are born 
with a genetic 
predisposition 
to getting lupus 
(more likely to 
have it because 
of their genetic 
background)  
4  4  2  67% 
19 ab Scientists 
believe that 
hormones, 
genetics, and 
the environment 
are all involved 
in causing lupus 
3  3 Hormones? 
Environment? 
-causing?-
modulating 
maybe not 
cause 
3  100% 
20 c Aging triggers 
lupus 
1  3  1  33% 
21 ab There are 
multiple types 
of lupus 
diagnoses 
4  4  2  67% 
22 ab Certain 
medications can 
cause lupus 
symptoms  
4  4  3  100% 
23 b Lupus can be 
“caught” by 
sharing 
personal items 
with someone 
who is 
diagnosed 
1  4  1  33% 
24 c Lupus is more 
common for 
Caucasians than 
for individuals 
of Hispanic, 
Asian, and 
Native 
American 
decent 
2  4  1  33% 
25 a Treatment can 
cure lupus 
1/4 ** This cannot be 
treated, but 
symptoms may 
be managed.  
 
4  2  67% 
26 d Treatment plans 
for lupus have 
been 
standardized 
and are all 
similar 
1/4 ** All patients have 
different 
manifestations of 
lupus, therefore 
treatment would 
be different. 
 
4  1  67% 
27 d Steroid 
medication has 
2  4  1  33% 
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the fewest 
negative side 
effects 
28 b Lupus is a 
predictable 
disease 
1  4  1  33% 
29 d Patients are 
encouraged to 
not exercise 
following 
diagnosis to 
help control 
disease 
progression 
1/4 ** All patients have 
different 
manifestations of 
lupus, therefore 
treatment would 
be different. 
 
4  1  67% 
30 a Being 
diagnosed with 
lupus places an 
individual at 
greater risk for 
additional 
medical 
diagnoses 
4 Lupus may affect 
multiple organs, 
which then may 
causes other 
diseases. 
 
4  1  67% 
31 b Patients are 
encouraged to 
minimize 
stressful life 
events 
4 stress may 
decrease immune 
system, and also 
flare symptoms  
 
4  3  100% 
32 c Bi-polar 
disorder is the 
most common 
co-occurring 
mental health 
diagnosis 
1  4  1  33% 
33 ab Women who 
have lupus and 
are pregnant are 
considered to 
have a “high 
risk” pregnancy 
4  4  3  67% 
34 d Lupus skin 
rashes that 
occur can be 
resolved easily 
with skin lotion 
1  4  1  33% 
35 ab Lupus can lead 
to difficulties 
with memory 
4  4  3  67% 
36 d Patients with 
lupus 
experience 
more digestive 
issues, causing 
them to need 
restrooms more 
often 
4  3  2  67% 
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37 d A diagnosis of 
lupus does not 
have a negative 
impact on a 
person’s ability 
to work 
1/4 ** this is a life 
changing 
diagnosis 
 
4  3  100% 
38 a Lupus increases 
an individual’s 
risk of 
premature 
cardiovascular 
disease (heart 
disease)  
4  4  4  100% 
a = items retained for the revised version based on CVI 
b = items retained for the revised version based on regression 
c = items retained for the revised version based on item difficulty/subjective 
d = items excluded from revised version 
(Of note, the items may or may not have gone through wording edits based off feedback between the draft version and the revised version) 
** = indicates items as their original score/score change after edits were accounted for 
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APPENDIX E:  
LKQ Items in CSM Dimensions 
Identity P1 P2 P3 CVI 
Jaundice is a common symptom 1 4 1 33% 
Kidney disease is the first disease indicator 1 4 3 67% 
Swollen/painful joint are common symptoms 4 4 2 67% 
Skin rashes are symptoms 4 4 3 100% 
Sun sensitivity is a concern 3 4 4 100% 
Hair loss is a symptom 4 4 3 100% 
Fatigue is not experienced 4 4 4 100% 
 
Cause P1 P2 P3 CVI 
Single gene causes lupus 1 2 1 0% 
Aging triggers lupus 1 3 1 33% 
Specific cause is known 1 4 1 33% 
Men diagnosed more 1 4 1 33% 
Same virus as HIV 1 4 1 33% 
Caucasian are diagnosed more than other ethnicities.  2 4 1 33% 
Immune system cannot distinguish cells 4 4 2 67% 
Genetic predisposition for lupus 4 4 2 67% 
African Americans more often diagnosed 4 4 3 100% 
Medications cause symptoms 4 4 3 100% 
Hormone, genes, environment all play a role 3 3 3 100% 
 
Time-line P1 P2 P3 CVI 
Can be caught by sharing items. 1 4 1 33% 
Lupus is diagnosed soon  1- Edits 4 3 67% / 100% 
“Immune count test” is the one test used. 1 4 3 67% 
 
Controllability/Curability P1 P2 P3 CVI 
Lupus is a predictable disease 1 4 1 33% 
Patients are encouraged to not exercise 1 4 1 33% 
Steroid medications cause least side effects. 2 4 1 33% 
Treatment can cure lupus. 1- Edits 4 2 33% / 67% 
Treatments are standard/similar. 1- Edits 4 1 33% / 67% 
Symptom Severity is the same for patients 2- Edits 4 1 33% / 67% 
Additional diagnoses are common after lupus. 4 4 1 67% 
Patients are encouraged to minimize stress. 4 4 3 100% 
 
Consequence  P1 P2 P3 CVI 
Bi-polar is the most common co-morbid mental health. 1 4 1 33% 
Skin lotion can eliminate rash symptoms 1 4 1 33% 
There are multiple types of lupus diagnoses.  4 4 2 67% 
Digestive issues are increased 4 3 2 67% 
Patients have negative work abilities 1- Edits 4 3 67% / 100% 
Lupus is also known as the Great Imitator. 4 3 3 100% 
Patients have memory concerns 4 4 3 100% 
Mothers with lupus will have a high risk pregnancy 4 4 3 100% 
Premature heart disease is a risk 4 4 4 100% 
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APPENDIX F:  
Draft LKQ Version 
Instructions: Please complete the following questionnaire that contains 38 items that will ask you about your 
general knowledge about systemic lupus erythematosus, more commonly referred to as lupus. The items are all 
designed as True/False or Don’t Know. Please answer the following items based on your current level of knowledge 
about lupus and be as honest as you can.  
 
 Item True False DK 
1 Fatigue is rarely experienced for lupus patients  False  
2 The “immune count test” is the one test used for diagnosing lupus  False  
3 Lupus increases an individual’s risk of premature cardiovascular disease (heart 
disease)  
True   
4 Women who have lupus and are pregnant are considered to have a “high risk” 
pregnancy 
True   
5 Steroid medication has the fewest negative side effects  False  
6 Patients with lupus experience more digestive issues, causing them to need to 
use restrooms more  
True   
7 Men are more likely to be diagnosed with lupus than women  False  
8 Lupus is caused by the same virus that is linked to HIV  False  
9 African Americans are more likely to be diagnosed over other racial groups True   
10 Lupus is a predictable disease  False  
11 Scientists believe there is a single gene that causes lupus  False  
12 Skin rashes are symptoms of lupus True   
13 The degree of symptoms in people with lupus are very similar  False  
14 Being diagnosed with lupus places an individual at greater risk for additional 
medical diagnoses 
True   
15 Aging triggers lupus  False  
16 There are multiple types of lupus diagnoses True   
17 Yellowing of the skin (jaundice) is a common symptom of lupus  False  
18 Lupus is often called “the great imitator” because lupus mimics other health 
conditions 
True   
19 Lupus is diagnosed soon after symptoms begin  False  
20 Swollen and painful joints are symptoms of lupus True   
21 A diagnosis of lupus does not have a negative impact on a person’s ability to 
work 
 False  
22 Treatment can cure lupus  False  
23 Scientists believe that hormones, genetics, and the environment are all involved 
in causing lupus 
True   
24 Hair loss is a symptom of lupus  True   
25 Patients are encouraged to minimize stressful life events True   
26 The specific cause of lupus has been identified by research scientists  False  
27 The immune system, of someone with lupus, cannot distinguish between healthy 
cells and harmful cells 
True   
28 Lupus can lead to difficulties with memory True   
29 Treatment plans for lupus have been standardized and are similar  False  
30 Patients are encouraged to not exercise following diagnosis to help control 
disease progression 
 False  
31 Kidney disease is one of the first indicators of lupus  False  
32 People are born with a genetic predisposition to getting lupus (more likely to 
have it because of their genetic background)  
True   
33 Certain medications can cause lupus symptoms  True   
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34 Lupus can be “caught” by sharing personal items with someone who is 
diagnosed 
 False  
35 Sensitivity to the sun is a concern for lupus patients True   
36 Bi-polar disorder is the most common co-occurring mental health diagnosis  False  
37 Lupus skin rashes that occur can be resolved easily with skin lotion  False  
38 Lupus is more common for Caucasians than for individuals of Hispanic, Asian, 
and Native American decent 
 False  
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APPENDIX G: 
Revised LKQ Version 
Instructions: Please complete the following questionnaire that contains 34 items that will ask you about your 
general knowledge about systemic lupus erythematosus, more commonly referred to as lupus. The items are all 
designed as True/False or Don’t Know. Please answer the following items based on your current level of knowledge 
about lupus and be as honest as you can.  
 
 Item True False DK 
1 Swollen and painful joints are symptoms of lupus. True   
2 Lupus can lead to difficulties with memory. True   
3 The onset of lupus is triggered by hormones, genetics and the environment. True   
4 Patients are encouraged to minimize stressful life events. True   
5 African Americans are more likely to be diagnosed over other racial groups. True   
6 The degree of symptoms in people with lupus is very similar.  False  
7 The immune system, of someone with lupus, cannot distinguish between healthy 
cells and harmful cells. 
True   
8 Certain medications can cause lupus symptoms. True   
9 Men are more likely to be diagnosed with lupus than women.  False  
10 Women who have lupus and are pregnant are considered to have a high risk 
pregnancy. 
True   
11 Lupus is a predictable disease.  False  
12 Lupus can be spread by sharing personal items with someone who is diagnosed.  False  
13 People are born with a genetic predisposition for lupus (more likely to have it 
because of their genetic background). 
True   
14 Being diagnosed with lupus places an individual at greater risk for additional 
medical diagnoses. 
True   
15 Lupus increases an individuals’ risk of premature cardiovascular disease (heart 
disease). 
True   
16 Fatigue is rarely experienced for lupus patients.  False  
17 The severity of symptoms is similar across patients.  False  
18 Lupus is often called the great imitator because lupus mimics other health 
conditions. 
True   
19 Hair loss/thinning is a symptom of lupus. True   
20 Please answer true for this item.  True   
21 Skin rashes are symptoms of lupus. True   
22 Sensitivity to the sun is a concern for lupus patients. True   
23 The immune count test is the one test used for diagnosing lupus.  False  
24 It may take many years to confirm a diagnosis. True   
25 The immune system of patients with lupus is weakened. True   
26 Lupus is diagnosed soon after symptoms begin.  False  
27 Bi-polar disorder is the most common co-occurring mental health diagnosis for 
lupus patients. 
 False  
28 Lupus is more common for Caucasians than for individuals of Hispanic, Asian, 
and Native American decent. 
 False  
29 It may take many years to confirm a diagnosis. True   
30 Aging triggers lupus.  False  
31 Kidney disease is one of the first indicators of lupus.  False  
32 Yellowing of the skin (jaundice) is a common symptom of lupus.  False  
33 There are multiple types of lupus diagnoses. True   
34 Treatment can cure lupus.  False  
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Figure 1: LKQ- draft Total Percentage (out of 100%, 38 items) 
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Figure 2: LKQ- revised Total Percentage (out of 100%, 34 items) 
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